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Abstract
Employing a combination of genetic and biochemical approaches, we have
recently shown that the 5’ end of MPMV genome (from the first nucleotide in R up
to 120 nt of Gag) contains a number of sequence and structural motifs important for
MPMV gRNA packaging and dimerization. A distinguishing feature of the higher
order structure of MPMV packaging signal RNA is two long-range interactions
(LRI) between U5 and Gag complementary sequences, LRI-I and LRI-II, which are
phylogenetically conserved among different MPMV strains. These LRIs have been
suggested to play a role in stabilizing the RNA secondary structure of the 5’ UTR
sequences that are important for MPMV RNA packaging.

The overall RNA

secondary structure of this region is further architecturally held together by three
other stem loops (SL3, Gag SL1, and Gag SL2) comprising of sequences from distal
parts of the 5’ UTR and Gag, excluding Gag sequences involved in forming U5-Gag
LRIs.
To provide functional evidence for the biological significance of U5-Gag
LRIs and the three stem loops to the MPMV life cycle, a series of mutations were
introduced in these structural motifs and their effects on MPMV RNA packaging and
propagation tested in a genetic trans-complementation assay. Test of LRIs mutants
revealed that disrupting the complementary base pairing of the LRI structural motifs
affected both gRNA packaging and propagation, confirming their functional role
during MPMV life cycle. Our results further revealed that the two LRIs function at
different levels.

Specifically, LRI-I functions at the secondary structural level,

whereas LRI-II functions at both the primary sequence as well as in its native
structural context levels. Finally, Mutational analysis of the sequences involved in

viii

forming SL3, Gag SL1, and Gag SL2 revealed that they do not play crucial role at
individual levels during MPMV gRNA packaging and propagation. These findings
suggest that U5-Gag LRIs have a more important architectural role in stabilizing the
structure of the 5’ UTR sequences, while the three stem loops (SL3, Gag SL1, and
Gag SL2) may have a more secondary role in stabilizing the overall RNA secondary
structure, providing a better understanding of the molecular interactions that take
place during MPMV gRNA packaging.

Keywords: Retroviruses; Mason-Pfizer monkey virus; RNA secondary structure;
RNA packaging; Long range interactions (LRI).
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)Title and Abstract (in Arabic
التجميع األمثل للمادة الوراثية ) (RNAلفيروس ) Mason-Pfizer Monkey Virus (MPMVيعتمد
على التفاعالت المحفوظة بعيدة المدى بين سلسلتي الحمض األميني المكونة ل  U5و Gag
لقد أظهرنا مؤخرا من خالل توظيف مزيج من األساليب الجينية والبيوكيميائية ،أن الطرف ' 5من جينوم
( MPMVمن النوكليوتيدات األولى في  Rتصل إلى  021في جين  )Gagيحتوي على عدد من الهياكل العليا
و سالسل نيوكليوتيدات ذات أهمية في عمليتي  dimerizationو التعبئة والتغليف packaging
لجينوم  . MPMVومن السمات المميزة للهياكل العليا المكونة إلشارة التعبئة والتغليف في جينوم MPMV
 RNAهو اثنين من التفاعالت طويلة المدى ( )LRIبين  U5وجينوم ،Gagهذه التفاعالت ملقبة ب LRI-I
و ،LRI-IIوالتي وجد أنها محفوظة  phylogeneticallyبين عدد كبير من سالالت  MPMVالمختلفة .هذا
ما اقترح أن هذه التفاعالت  LRIsقد تلعب دورا في استقرار و متانة الهيكل الثانوي ل  RNAبداية من
الطرف ' 5في تسلسل  UTRالتي تعتبر مهمة لعملية التعبئة والتغليف  packagingلجينوم .MPMV RNA
كما أن متانة هذا الهيكل الثانوي تعتمد بشكل عام على وجود ثالثة حلقات جذعية  stem loopsأخرى تسمى
( )Gag SL2 ، Gag SL1 ،SL3و تتألف من اقتران سالسل نيوكليوتيدات من أجزاء من الطرف 5' UTR
وجينوم  ،Gagباستثناء األجزاء من جينوم  Gagالمشاركة في تشكيل تفاعالت .LRIs
لتقديم أدلة وظيفية لألهمية البيولوجية لتفاعالت  LRIsوالحلقات الجذعية الثالثة في دورة الحياة
MPMVخاصة عمليتي تكوين ثنائي الجينوم  RNA dimerizationو التعبئة و التغليف ،packaging
أدخلت سلسلة من الطفرات في هذه الزخارف الهيكلية الثانوية و تم فحص آثارها على عمليتي تكوين ثنائي
الجينوم  RNA dimerizationو التعبئة و التغليف  packagingباستخدام genetic trans-
 .complementation assayوكشف هذا االختبار أن الطفرات التي تسببت بتعطيل تكون تفاعالت اقتران
هياكل ال  LRIsقد أثر سلبيا على كل من عمليتي تغليف الجينوم  RNA packagingو التكاثر
 propagationمؤكدا الدور الوظيفي للهياكل العليا الثانوية  LRIsأثناء دورة حياة  .MPMVوكشفت النتائج
التي توصلنا إليها كذلك إلى أن كل هيكل من  LRIsتؤدي وظيفتها بطريقة تختلف عن األخرى .فعلى وجه
التحديد ،تؤدي تفاعالت اقتران هيكل  LRI-Iوظيفتها على المستوى الهيكلي الثانوي ،في حين أن وظائف
تفاعالت اقتران هيكل  LRI-IIتؤدي وظيفتها باالعتماد على التسلسل األساسي للنوكليوتيدات المشاركة في هذا
االقتران باإلضافة إلى الهيكل الثانوي على حد سواء.
أخيرا ،كشف تحليل الطفرات أن تسلسل النوكليوتيدات المشاركة في تكوين الحلقات الجذعية الثالثة المسماة ب
 ،Gag SL1 ،SL3و  Gag SL2أنها ال تلعب دورا حاسما على المستوى الفردي خالل عمليتي تغليف
الجينوم  RNA packagingو التكاثر propagationل  .MPMV gRNAهذه النتائج تشير إلى أن
تفاعالت اقتران النوكليوتيدات من  Gag-U5المكونة ل  LRIsلها الدور المعماري األكثر أهمية في تحقيق
االستقرار في هيكل تسلسل  ،5' UTRفي حين أن الحلقات الجذعية الثالثة ( ،Gag SL1 ،SL3و SL2
 )Gagقد يكون لها دور أكثر ثانوية في استقرار الهيكل الثانوي ل  MPMV RNAبشكل عام ،و بالتالي فإن
هذه النتائج توفر فهم أفضل للتفاعالت الجزيئية التي تحدث أثناء عملية تغليف  MPMV gRNAمما يساعد
على استخدامها بشكل آمن في المستقبل في عالج األمراض الوراثية .gene therapy
ع بارات م ف تاح ية :
ت فاع الت طوي لة اىدمل ،االم راض ال وراث ية  ،ال ه ي كل ال ثان وي  ،ت غ ل يف ال ج ي نوم
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Chapter 1: Introduction
1.1.

Retroviruses in a Nutshell
Since the early 1900's, substantial insights pertaining a new family of viruses

have been introduced to the scientific community. These viruses received more
attention when they were implicated as the causative agents for leukemia in chicken
by Peyton Rous in 1911. Later on in 1970, the revolutionary discovery of the unique
enzyme, reverse transcriptase (RT) from this group of viruses by Howard Temin and
David Baltimore shattered the central dogma of molecular biology. The presence of
RT in these viruses was able to reverse the flow of genetic information and thus they
were named as "Retroviruses''. In brief, retroviruses are a large group of viruses
belonging to the Retroviridae family. They are enveloped viruses and their single
stranded RNA genome of positive polarity is linear, non-segmented, and
approximately 7-12 kilobases (kb) in size. Over the years, retroviruses have been
associated with a variety of diseases, mainly cancers and immunological
deficiencies, both in animals and humans.
As their name indicates, retroviruses are characterized by their replication
strategy which involves the activity of the virally-encoded RT enzyme which reverse
transcribes the viral RNA into double stranded DNA. This viral DNA is then
integrated into the host chromosomes by the virally-encoded enzyme, integrase (IN),
allowing its stable expression and making it part of the host genome. This is why
retroviruses are retroviral for human gene therapy trials (reviewed in Verma and
Weitzman, 2005).

2

1.2.

Retroviral Genome Organization
Among the various types of RNA viruses, retroviruses are exclusively known

for packaging two copies of their RNA genome (diploid) as a dimer linked at the 5'
end with non-covalent interactions (reviewed in Pedersen and Duch, 2006).
Retroviral genomic RNA (gRNA) harbors two types of sequences: non-coding
sequences that facilitate and control many essential steps during the virus replication
(reviewed in Kuzembayeva et al., 2014), and coding sequences that encode for the
structural and enzymatic proteins of the virus (Figure 1.1). A typical retrovirus
genomic RNA contains a unique sequence at the 5’ end called U5 and one at the 3’
end called U3. Both the U5 and U3 are juxtaposed with the same repeated sequence
“R” forming the cis- controlling elements of the viral genome. Retroviral genome
organization changes when the RNA genome is reverse transcribed into DNA during
which the U5 is copied to the 3’ end of the genome and the U3 sequence gets copied
to the 5' end, forming a long terminal repeat (LTR) at both ends of the viral DNA
(Figure 1.1).
Next to the U5 and U3 sequences is a stretch of non-coding sequences at the
end called 5' end and sometimes at the 3' end called untranslated region (UTR)
flanking the protein-coding sequences. The 5’ UTR is characterized by the presence
of primer binding site (PBS), whereas the 3’ UTR is characterized by the presence of
polypurine tract (PPT) both of which play pivotal roles during reverse transcription
of the RNA genome. Over the years, it has been shown that that sequences within
the 5’ UTR have an essential role in the viral gRNA (gRNA) dimerization and
packaging (reviewed in Paillart et al., 2004; Russell et al., 2004; D’Souza &
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Figure 1.1. Schematic representation of the retrovirus genome. (A) The
retrovirus genomic RNA contains both coding and non-coding sequences. The noncoding sequences are located at the 5’ and 3’ ends of the genome. These sequences
contain essential recognition sites for DNA synthesis, integration and
polyadenylation. The primer binding site (PBS) and the polypurine tract (PPT)
sequences play an important role during reverse transcription. The coding sequences
of the viral genome comprises gag gene which encodes group-specific structural
antigens, the pol gene which encodes for the reverse transcriptase, integrase and
protease enzymes, and the envelope (env) gene which encodes for the envelope
structural proteins. As the complexity of the retrovirus genome increases, it acquires
additional genes that help in the completion of its life cycle. (B) The viral DNA
genome after being reversed transcribed from the RNA template. It acquires an extra
copy of the unique 3’ sequence at its 5’ terminal (U3) end and an extra copy of the
unique 5’ sequences at its 3’ terminal end (U5), forming an identical flanking
sequence called long terminal repeat (LTR).
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Summers, 2005; Johnson & Telenitsky, 2010; Lever, 2007; Lu et al., 2011;
Kuzembayeva et al., 2014).

The structural genes of the virus are encoded in-between these controlling elements.
For example, a simple retrovirus like Mason-Pfizer monkey virus (MPMV) harbors
three open reading frames (ORFs): gag, pol, and envelope (env; Figure 1.1). The
gag gene encodes for group specific antigen (Gag) precursor structural polyprotein
which, upon maturation of the virus particle, is cleaved by the viral protease into
structural proteins; capsid (CA), matrix (MA), and nucleocapsid (NC) (Figure 1.2).
The capsid (CA) proteins form the viral core which contains the viral gRNA as well
as other viral enzymes and proteins, while the matrix (MA) mediates the stable
association of the envelope proteins into the virus particle.

The role of the

nucleocapsid (NC) protein is to selectively bind the unspliced gRNA, facilitating its
packaging into the virus particle. The pol ORF encodes for the viral enzymatic
proteins, namely RT, IN and protease (PR; Figure 1.2). As mentioned above, RT
mediates the reverse transcription of the RNA genome into DNA, IN facilitates the
integration of the reverse transcribed DNA genome into the host chromosomes, and
PR is responsible for cleaving the Gag/Pol polyproteins into mature structural and
enzymatic proteins.

The env gene encodes for the envelope precursor protein

which gets cleaved by cellular proteases into the transmembrane (TM) and surface
(SU) glycoproteins (gps) which are then incorporated into the phospholipid
membrane that is acquired from the host cell membrane through the process of
budding (Figure 1.2). Throughout the evolutionary process, as the complexity of the
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virus increases, it sometimes becomes necessary for the virus to acquire more genes
to fulfill its survival needs in a new and perhaps more complex hosts. For example,
human immunodeficiency virus type-1 (HIV-1) has been shown to have six
additional and/or accessory genes (vif, vpr, vpu and nef, tat, and rev; Figure 1.3;
reviewed in Balvay et al., 2007; Cullen & Green, 1990; Pavlakis & Felber, 1990).
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Figure 1.2: Schematic representation of a retrovirus particle.
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Figure 1.2. Schematic representation of a retrovirus particle. The retroviral
genome consists of a diploid single stranded RNA wrapped by structural proteins
encoded by the gag gene, including the nucleocapsid, capsid and matrix proteins. In
addition, non-structural enzymatic proteins encoded by the pol gene (reverse
transcriptase, protease and integrase) are also packaged into the virus particle.
During the process of budding, the virus acquires lipid bilayer from the host into
which the virally-encoded envelope glycoproteins (TM and SU) are anchored.
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1.3.

Retrovirus Life Cycle:
The life cycle of a retrovirus can be divided into two phases, namely

extracellular and intracellular (Figure 1.4). In the extracellular phase, the virus
recognizes and binds to its host cell via ligand-receptor interaction between the virus
envelope proteins and its specific receptor on the host cell membrane (Figure 1.4A).
Upon binding, the virus membrane fuses with the host cell plasma membrane thus
initiating the intracellular phase of the life cycle. Binding may also require a coreceptor to strengthen the binding and bring the two membranes closer, thus
facilitating the fusion. Once inside the cell, RT starts reverse transcription of the
gRNA and converting it into a double stranded DNA. The reverse transcribed viral
DNA then moves to the nucleus, where IN mediates the process of its integration
into the host genome. At this stage, the integrated retroviral DNA is called a
“provirus”.

Now the double stranded DNA is transcribed by the cellular

transcription machinery into two different categories RNAs, namely spliced and
unspliced RNAs. Both of these types of RNAs are then exported out of the nucleus
to the cytoplasm for two different functions (Figure 1.4B). The spliced env mRNA
is translated to make the envelope glycoproteins.

On the other hand, the unspliced

gRNA plays dual functions: 1) it acts as a template for translation of Gag/Pol
precursor polyproteins, and 2) it acts as the genome for incorporation into the
assembling virus particles.

HIV-1

MPMV

Figure 1.3.:Schematic representation of different retroviruses genomes
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Figure 1.3. Schematic representation of different retroviruses genomes. Typical
simple retroviruses like Mason –Pfizer Monkey Virus (MPMV) has three canonical
coding genes: gag, pol and env.

They maintain a constitutive transport element

(CTE) at the 3’ untranslated region (UTR) which helps in the nucleo-cytoplasmic
export of their RNAs.

Complex retroviruses like HIV-1 code for additional

accessory and regulatory proteins. It also contains the Rev protein which binds to
specific sequences called Rev-Responsive Element (REE) to allow its unspliced and
singly-spliced RNAs to get exported from the nucleus.

(A)
A

(B)

Figure 1.4: Overview of retroviruses life cycle
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Figure 1.4. Overview of retroviruses life cycle. Retroviruses recognize and bind to
specific host cells via their envelope proteins. After entry, the genomic RNA gets
reverse transcribed to form double stranded DNA which gets imported into the
nucleus and integrates into the host genome to form the provirus. Once integrated,
the viral DNA gets transcribed using the host transcription machinery. Transcription
results in at least two different types of

RNAs, full-length unspliced and

singly/multiply spliced RNA, both of which get exported to the cytoplasm where the
unspliced genomic RNA express the Gag/Pol proteins and the spliced RNA expresses
the envelope and other proteins during the process of translation. Finally, the full
length unspliced genomic RNA gets packaged into the budding virus particle. Figure
adapted from Stoye, 2012.
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The Gag/Pol polyproteins resulting from the expression of the unspliced RNA are
cleaved by a virally-encoded protease to give CA, MA, and NC proteins, whereas
the envelope precursor glycoprotein is cleaved by cellular proteases into SU and TM
proteins. These structural proteins then assemble to form the virus particle (Figure
1.4B). The unspliced full-length gRNA interacts with the NC portion of the Gag
protein near the plasma membrane and the two copies of the gRNAs are
encapsidated as a dimer. While budding from the host cell, the virus particles
acquire part of the host-plasma membrane along with the incorporated envelope
glycoproteins.

After being released, the virus particle matures and becomes

infectious by further proteolytic cleavage and gRNA dimer stabilization (Bender et
al., 1978; Murti et al., 1981; Fu and Rein, 1993).
The following sections discuss the retrovirus replication steps in more details.

1.3.1. Attachment and Entry
In order for the retrovirus to establish intracellular aspect of its life cycle
inside the host cell, it should attach to the cell plasma membrane, which is the rate
limiting step of the infection process. Attachment to the target cell membrane is a
distinct step from the entry and uptake of the retrovirus. This process requires an
entry receptor and may require co-receptors to assist with the entry process. For
example, in HIV-1, in addition to the CD4 receptor, another co-receptor is required
that differ in different cell types. The T-cells have been shown to use CXCR4 while
macrophage-tropic HIV-1 viruses use CCR5 as the co-receptor. (Reviewed in
Clapham PR., and McKnight A., 2001). The binding itself doesn’t allow for the virus
entry, however, it is the viral envelope fusion with the host cell plasma membrane
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that facilitates its entry. Retroviral envelope glycoproteins are arranged as oligomers
of the globular SU domain anchored to the viral membrane by the TM domain.
Upon attachment it has been shown that the oligomeric nature of the envelope
glycoproteins favors the clustering of cell receptors where soluble monomeric
glycoproteins can each interact with the receptor to allow for an efficient entry.
Such has been observed when the monomeric mouse mammary tumor virus
(MMTV) gp51 binding was found to be insufficient to promote receptor
internalization (we should cite the appropriate reference here). In addition to the
clustering strategy, sequential binding of envelope glycoproteins may result in
receptor aggregation and thus competent attachment. Conformational changes in the
SU domain upon binding expose a hydrophobic peptide in the TM domain that is
essential for catalyzing the fusion between viral and cellular membranes. Even
though the steps involved in the fusion process are still not fully understood, it seems
that the end step includes the formation of a fusion-pore (Muno z-Barroso et al.,
1998). As the virus envelope gets fused with the cellular membrane, the virus
releases its internal component into the cell cytoplasm where it becomes ready for
the first step of the intracellular phase of the virus life cycle that is the reverse
transcription.

1.3.2. Reverse Transcription
A unique characteristic of retroviruses is the non-conventional way they
continue their life cycle, exploiting the exceptional activity of RT which can convert
the viral diploid single stranded RNA genome into double stranded DNA (Figure
1.5A). RT is capable of “reverse” replication because of its two distinct activities:
RNA dependent DNA polymerase (RDDP) and DNA dependent DNA polymerase
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Figure 1.5: Schematic representation of the steps involved in reverse transcription.
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Figure 1.5. Schematic representation of the steps involved in reverse
transcription. (A) Schematic representation of the flow of the genetic information
of a retrovirus genome . (B) The reverse transcription process is mediated by a
virally encoded enzyme called reverse transcriptase (RT) and involves two transfer
steps. It begins with binding of tRNA primer to the primer binding site (PBS) at the
5’ end. DNA synthesis begins till the end of the template is reached. This initiates
the first of the two transfer steps in the reverse transcription process.. The first
intermediate (-) strand DNA synthesized at the 5’ end is transferred to the 3’ end
during (-) strong-stop template switch. Then RNA template from the DNA:RNAhybrid gets degraded by RNase H as the (-) strand synthesis proceeds, except
polypurine tract (PPT) which is RNase resistant and functions as a primer for (+)
strand DNA synthesis. During the second transfer, the (+) strand product that results
from synthesis into the tRNA primer is transferred to the 5’ end of nascent (-) strand
DNA during (+) strand strong stop transfer.

The resulting DNA contains two

terminal repeats (LTRs) each consisting of the terminal block of U3-R-U5. Figure
adapted from Telestinsky & Goff , Reverse Transcriptase and the Generation of
Retroviral

DNA.
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(DDDP). RT also contains a nuclease activity termed Ribonuclease H (RNase H)
that degrades the RNA strand from the RNA: DNA duplexes. A role of some of the
viral proteins like the nucleocapsid protein in the reverse transcription process has
also been shown to be important for an efficient RT process (Levin et al., 2010).
The reverse transcription process initiates once the virus enters the host cell, except
for the genus Spumavirinae in which a mature virion was found to already contain
reverse transcribed DNA in addition to RNA (Yu et al., 1996). The key players in
the reverse transcription process that act in cis are PBS, PPT, and the R sequences on
the termini of retroviral gRNA. Various steps involved during the course of reverse
transcription process are delineated in (Figure 1.5) and described in detail below.
Once the virus capsid is released into the host cell cytoplasm, a cell-derived
tRNA primer binds to its complimentary sequence on retroviral PBS while still
inside the virion capsid. Next, the RDDP activity of RT starts making a copy of the
viral DNA from the PBS and stops at the 5’ end followed by degradation of the RNA
portion of the RNA: DNA hybrid by the RNase H activity of RT. This results in the
formation of the minus strand strong stop DNA (-sss DNA) (Figure 1.5B). Now RT
is ready for the minus strong stop template switch where it jumps to the 3’ end of the
gRNA and anneals to the redundant terminal R sequences (Figure 1.5B). This
primes the synthesis of the minus strand DNA which takes place as the RNA
template is being degraded by RNAse H. To initiate the synthesis the DNA plus
strand, another primer at the 3' end is needed for the priming purposes. Since PPT
sequence is resistant to the hydrolysis by the RNAse H activity of RT, therefore it
plays the role of a primer for the synthesis of plus strand DNA (Figure 1.5B). At
this stage the RT utilizes its DDDP activity and the minus strand DNA as a template.
The synthesis proceeds upto the 5' end of the genome and stops at the first nucleotide
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at the 3’ end of the tRNA sequence that anneal to the PBS generating a new PBS
sequence. At this point the tRNA is digested by the RNase H activity of the RT and
the resulting +sssDNA will have a copy of the 3’ end U3 at the 5’ end and a copy of
the 5’ end U5 at the 3’ end. During reverse transcription, recombination among
retroviruses can occur during the synthesis of both minus and plus strand DNA
synthesis (Hu and Temin, 1990).

The recombination between retroviral RNAs

during reverse transcription is considered a serious problem, especially if the cell is
co-infected with two different strains of viruses, where the recombination could
result in the formation of a new virus of unknown biology and pathogenic potential.
Emergence of such new variants among retroviruses poses a major threat towards the
development of antiviral agents and viral vaccines.

Therefore, it is not at all

surprising that the first approved anti-HIV drug, AZT, targeted RT and of the 26
currently approved drugs to treat HIV-1 infections, 14 are RT inhibitors (Hu and
Hughes, 2012).

1.3.3. Integration
Following reverse transcription, the newly formed retroviral DNA must be
imported to the host cell nucleus for integration into the host genome in order to
continue its life cycle. The integration process is a hallmark of retroviruses making
them good candidates for gene therapy since they can to maintain long-term
expression of the integrated therapeutic gene.
The integration process is primarily mediated by the virally encoded IN
enzyme. IN, with the help of some other viral proteins that differ from one group of
retroviruses to the other, forms the pre-integration complex (PIC). Migration of PIC
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to the nucleus occurs in two different ways.

The first route is observed in

oncoretroviruses, viruses that require the cell to be in the dividing state so that the
newly reverse transcribed DNA can gain access to the nuclear DNA when the
nuclear membrane is disassembled during mitosis.

However, since HIV-1 in

particular and the lentiviruses in general can infect nondividing cells, such a strategy
cannot be exploited by HIV-1 or other lentiviruses. Consequently, there must be a
second route through which the HIV-1 PICs can enter the nucleus. It has been
shown that HIV-1 PICs can enter the nucleus during the interphase in an energydependent import process through the nuclear pore apparently via nuclear
localization signals (NLS) found in the viral MA and the Vpr proteins (Bukrinsky et
al., 1993).
Once inside the nucleus, integration into the host chromosome involves a
series of nucleophillic attacks, the first of which removes the terminal 2 bases from
the 3′ ends of the LTRs that are recognized by viral IN (Fig 1.6), whereas the second
attack inserts the viral DNA into the host genome.

The site of integration is

recognized by the viral IN and is characterized by duplication of the host target site
following integration. In addition to the viral proteins, at least two host cellular
proteins, high mobility group [HMG-I(Y)] and barrier to autointegration factor
[BAF], have been shown to increase the efficiency of the integration reaction (Van
Maele et al., 2006). The viral proteins that are used for integration might have other
roles like directing the assembly of transcription factors or other cellular proteins
onto the newly integrated provirus. The integration process of retroviral DNA into
the host genome while being a critical step for the virus to continue its life cycle, at
the same time, it poses a great concern to the scientific community when it comes to
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Figure 1.6. Retroviral DNA integration
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FIGURE 1.6. Retroviral DNA integration. The virally encoded integrase enzyme
recognizes and nicks both ends of the viral DNA. It removes 2 or 3 nucleotides from
each of the 3’ ends of

the double stranded DNA. It also

introduces random

staggered nicks in the host DNA via the exposed hydroxy (OH) groups on the viral
DNA ends. This results in simultaneous joining of the 3′ end of the viral DNA and
the 5′ end of the target DNA. This results in an integrated retroviral genome called a
“provirus”. A consequence of this process is duplication of the “target site” which is
signature of a successful integration process. Figure adapted from Yasutsugu et
al.,2012.
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the use of viral vectors in gene therapy since their integration could cause
oncogenesis.

Retroviral integration is a random process and lentiviral vectors

integrate more randomly than the viral vectors throughout the human genome;
however, it has been shown that retroviral vectors favor promoters and enhancer
regions as preferred integration sites (Schroder et al., 2002). Swapping IN between
closely related retroviruses has been shown to change the integration pattern
suggesting that the catalytic core of the IN play a role in choosing the preferred site
of insertion (Shibagaki et al., 1997). Recently, a lot work is being undertaken to
achieve site directed retroviral integration which could possibly avoid the risk of
oncogenesis by retroviral vector insertional activation (reviewed in Youngsuk et al.,
2011).

1.3.4. Transcription
Using the cellular transcription machinery, the integrated proviral DNA is
transcribed along with the cellular DNA to generate mRNAs needed for viral protein
production. Specifically, transcription of the proviral DNA produces full length
unspliced gRNA that plays a dual role (as mentioned earlier): as an mRNA for the
translation of the Gag/Pol polyproteins, and also as a substrate to be packaged into
the newly assembled virus particle as gRNA. It has been shown that cellular RNA
Polymerase II is responsible for proviral DNA transcription since it has cis-acting
sequences that direct RNA polymerase II in the production of mRNAs. The
polymerase II processivity has shown to be enhanced by the binding of some viral
transcriptional transactivators, such as Tat protein in the case of HIV-1 where it
binds to TAR on the viral mRNA, enhancing the binding of transcription factors to
DNA (reviewed in Jeang, 1999). The resulting transcribed viral RNA experiences
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the same processing events that cellular RNAs go through, including RNA splicing,
to yield different lengths of unspliced and spliced mRNAs. For example, in all
retroviruses, singly spliced mRNA is used for translating the envelope glycoproteins.

1.3.5. Retroviral RNA Nuclear Export and Translation
After being transcribed, processed, and spliced, the retroviral RNA is ready
to be exported from the nucleus to the cytoplasm. However, the splicing machinery
inhibits the unspliced or singly spliced RNA, from being exported out of the nucleus,
a phenomenon called nuclear retention.

To overcome such nuclear retention,

retroviruses have evolved mechanisms that allow them to successfully export,
especially the unspliced RNAs, out of the nucleus. One way by which retroviruses
overcome nuclear retention is by the presence of a regulatory pathway in which cisacting RNA structural elements found at the 3’ end of retroviral gRNA interact
either with the virally encoded or cellular proteins to facilitate the successful export
of the unspliced gRNA. One example of such a structure is the constitutive transport
element (CTE) in the case of the simple retrovirus MPMV (Figure 1.7; Bray et al.,
1994; Rizvi et al., 1996a and 1996b; Ernst et al., 1997). MPMV CTE interacts with
cellularly-encoded nuclear export factor 1 (NXF1) or Tap that facilitates export and
expression of CTE-containing mRNAs (reviewed in Cochrane et al., 2006; Swanson
and Malim, 2006). In complex retroviruses, a virally-encoded protein, such as Rev
in the case of HIV-1 interacts with an RNA element at the 3’ end called Rev
responsive element (RRE), to allow nuclear export of viral messages (reviewed in
Groom et al., 2009; Figure 1.7). Similarly, MMTV has evolved the Rem/RemRE
regulatory pathway in which the Rem protein interacts with cis-acting RemRE
sequence located at the 3' end of the viral transcripts (Figure 1.7). Recently, it has
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been shown that gamma retroviruses also contain a post transcription element (PTE),
a cis-acting sequence which overlaps the pro-pol open reading frame and is
responsible for the regulation of gag gene expression (Pilkington et al., 2014). The
PTE function resembles that of the CTE function in the case of MPMV, but the
location is different from the usual one at the 3’ end.

Once successfully exported out of the nucleus, the retroviral RNA is
translated into viral proteins, a process that is mediated by the host translational
machinery (reviewed in Balvay et al., 2007).

The Gag/Pol viral proteins are

translated from the unspliced gRNA by the free cellular polyribosomes, whereas the
envelope glycoproteins are translated from the spliced mRNA by the rough
endoplasmic reticulum-bound ribosomes. The translated envelope precursor protein
undergoes post translational modifications.

It undergoes N-glycosylation in the

lumen of the endoplasmic reticulum and is cleaved at its SU-TM border by host
proteases within the Golgi apparatus as it is transported for incorporation into the
host cell membrane.

Figure 1.7: Nucleo-cytoplasmic export pathways of unspliced or partially spliced retroviral RNAs
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Figure 1.7. Nucleo-cytoplasmic export pathways of unspliced or partially
spliced retroviral RNAs. Sufficient amounts of retroviral unspliced RNA needs to
be exported to the cytoplasm to get translated into the structural and enzymatic
proteins needed for virus survival as well as to be packaged as genomic RNA into
the newly assembled virus particles. Number of retroviruses have evolved different
mechanisms to facilitate this nuclear export. A. In complex retroviruses, such as
HIV-1, a cis acting structural element called rev responsive element (RRE) binds to
virally encoded trans acting proteins (REV) to facilitate the efficient export of
unspliced RNAs from the nucleus to the cytoplasm. B. Simple retroviruses such as
MPMV, harbor a cis-acting constitutive transport element (CTE), which interacts
with cellular proteins to export full length viral RNAs from the nucleus to the
cytoplasm. C. “semi-complex” retroviruses such as MMTV have been shown to
contain a cis-acting Rem-Responsive Element (RmRE) at the 3’ end of the genome,
which interacts with virally encoded trans proteins called Rem, to efficiently export
MMTV RNA to the cytoplasm. Figure adapted from Jaballah, 2010.
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The viral Gag and Pol ORFs overlap and the Gag and/or Gag/Pol
polyproteins are translated from the unspliced mRNA in a ratio of 20 Gag products
to one Gag-Pol product on free ribosomes (reviewed in Pederson and Duch, 2006;
Lever, 2007). Due to the overlapping nature of Gag and Pol ORFs, the translation
process is paused at a certain stage to allow the ribosome to shift from translating
Gag ORF to Pol ORF. Such a translational switch has been shown to occur in two
different ways. In the first way, as in the case of gamma retrovirus, the Moloney
murine leukemia virus (MoMLV), translation termination is suppressed by
misreading the stop codon. This process shifts the reading from Gag to Pol ORF and
thus translating the downstream POL ORF (Yoshinaka et al., 1985; Honigman et al.,
1991).

The second mechanism (used by most retroviruses) is a frameshift

mechanism, in which the ribosomes slips backward by one nucleotide, thus changing
the reading frame it is translating in- a process called ribosomal frameshifting
(Figure 1.8). This process involves the

Figure 1.8: Schematic representation of ribosomal frameshifting phenomenon in retroviruses to express relative amounts of
Gag and Pol proteins.
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Figure 1.8. Schematic representation of ribosomal frameshifting phenomenon
in retroviruses to express relative amounts of Gag and Pol proteins. Retroviral
gRNAs contain “slippery” sequences that allow ribosomes to move to a different
reading frame and continue translation by a process known as “ribosomal
frameshifting”. Briefly, the mRNA folds into a RNA secondary structure containing
a stem loop which is located just downstream of the slippery sequence. This stem
loop causes ribosomes to pause at the position of the slippery sequence during
translation, which in turn results in increased frequency of ribosomal frameshifting.
Frameshifting enables a higher translation rate of proteins encoded by the
downstream reading frame. Figure adapted from Alberts et al., 2002.
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ribosomal frameshift signal (RFS) comprised of a reiterated sequence and an RNA
secondary structure, the pseudoknot present downstream of the RFS (reviewed in
Brierley and Dos Ramos, 2006). Programmed ribosomal frameshifting in HIV-1 and
the SARS-CoV. Virus Res., 119: 29-42).

Most ribosomes encountering RFS translate it without difficulty and continue
along the transcript until a translation stop codon is reached. During this process, a
proportion of the ribosomes which attempt to translate this sequence slip back by
one nucleotide before continuing to translate the message in a different reading
frame. Because of this, the sequence has been termed the “slippery sequence”
(Figure 1.8). The slippery sequence alone only results in a low frequency of frame
shifting, inadequate to produce the amount of protease and reverse transcriptase
protein required by the virus. There are additional sequences that further regulate
this system and increase the frequency of frame shift events. A short distance
downstream of the slippery sequence is an inverted repeat which allows the
formation of a stem-loop structure in the mRNA (Figure 1.8). There is an additional
sequence complementary to the nucleotides in the loop which allows base-pairing
between these two regions of the RNA, allowing the formation of what is known as
an RNA “pseudoknot”. This secondary structure in the mRNA causes ribosomes
translating the message to pause at the position of the slippery sequence and this
slowing or pausing of the ribosome during translation increases the frequency at
which frame shifting occurs, boosting the relative amounts of the proteins encoded
by the downstream reading frames (Figure 1.8).
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1.3.6. Translation and Packaging of Retroviral gRNA
A close relationship between retroviral gRNA translation and packaging
exists as a result of the dual role of the full length unspliced gRNA since it functions
as the precursor for Gag/Pol protein expression as well as the substrate to be
packaged into the virus particles. Two possible scenarios describe what happens at
this stage (Figure 1.9) (reviewed in Balvay et al., 2007). The first scenario suggests
that the unspliced RNA exclusively gets translated into Gag/Pol precursors until a
sufficient amount of proteins start to accumulate in the cytoplasm. At this stage, the
Gag polyproteins start interacting with the packaging signal within the 5’ UTR of the
unspliced gRNA. This process results in the progressive occlusion of the 5’ UTR as
the ribonucleoprotein scaffold is formed. Since, the same RNA that is used for
translation is to be packaged into the assembling virus particle therefore in an
alternative scenario, the viral Gag/Pol precursor proteins are translated from the
unspliced gRNA constitutively.

The resulting Gag proteins bind to another

unspliced gRNA strand in the pool of unspliced RNA present in the cytoplasm. The
two mechanisms are believed to be mutually exclusive (Balvay et al., 2007).

1.3.7. Virus Assembly
The viral gRNA represents only a small fraction of the total RNAs present in
the infected cell. However through a very selective and discrete process, only two
copies of the viral gRNA as a dimer are packaged in the newly assembled virus. To
unravel the mechanism(s) by which the virus encapsidate its gRNA in such a
discrete manner one must understand the intricacies involved during gRNA
dimerization and packaging.

Figure 1.9: Translational control of retroviral genomic RNA packaging.
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Figure 1.9. Translational control of retroviral genomic RNA packaging. After
having integrated into the host genome, the retroviral genome undergoes
transcription and splicing followed by the transport of both full length and spliced
RNAs to the cytoplasm. The full length unspliced RNA has two roles to play and the
mechanism by which its fate is decided can be described in two scenarios. In
scenario (a), the genomic RNA (gRNA) undergoes translation to form Gag and Gagpol proteins (not shown). Upon the accumulation of Gag molecules, a switch from
translation to packaging happens, allowing the Gag proteins to bind the gRNA
(shown in black) at the 5′ end to the packaging signal and proceed to the assembly
step. Whereas in scenario b, the gRNA is translated continuously and the resulting
Gag proteins bind the gRNA which was not translated (shown in red). Figure adapted
from Balvay et al., 2007.
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1.3.8. Retroviral Genomic RNA Dimerization
The dimerization process is considered to be one of the most critical steps
during the retroviral life cycle as it is essential to form the non-covalently linked
RNA dimers that can be packaged in the assembling virus particles (reviewed in
D'souza & summers, 2005; Johnson & Telestnitsky, 2010; Lever, 2007).
Dimerization begins at the dimerization initiation site (DIS), which is invariably a GC rich palindromic (pal) sequence and often present in the form of a loop (at the 5’
end of gRNA), facilitating its interaction with the DIS loop on the second gRNA
(Laughrea et al., 1996; Paillart et a., 1996 and further reviewed in D'souza &
summers, 2005; Johnson & Telestnitsky, 2010; Lever, 2007; Figure 1.10). Three
DIS motifs consisting of 6 nucleotides pal sequences (GCGCGC, GTGCAC and
GTGCGC) have been reported in multiple HIV-1 isolates (Berkhout, B., and van
Wamel, 1996; Clever et al., 1996; Laughrea et al., 1997; Laughrea et al., 1999).
Among these, a DIS motif consisting of a characteristic 6 nt pal (GCGCGC) has
been found to be phylogenetically conserved in over 50 HIV-1, HIV-2 and SIV
isolates (Russell et al., 2004). In addition, it has been shown that a 10 nt pal
sequence in the 5’ UTR, which is phylogenetically conserved in HIV-2 and macaque
and sooty mangabey SIVs (Leitner et al., 2005), is crucial for HIV-2 RNA packaging
and dimerization (Lanchy et al., 2003; Baig et al., 2007; Lanchy and Lodmell 2007).
Finally, pal sequences that have been shown to function as DIS in augmenting
gRNA dimerization and packaging have also been observed in other retroviruses
such as Feline immunodeficiency virus (FIV) and MMTV (Kenyon et al., 2008;
Rizvi et al., 2010; Aktar et al., 2014). The base pairing between the two strands is
mainly maintained by the auto-complementarity between the palindromic sequences

Figure 1.10: Model depiction the steps leading to dimerization and packaging processes among retroviruses.
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Figure 1.10. Model depiction the steps leading to dimerization and packaging
processes among retroviruses. A schematic simulation of dimerization and gRNA
packaging in a co-infected cell with two different viruses. (A) Each virus particle
has a dimer-linked two identical RNAs packaged in its capsid. (B) The gRNA inside
the cytoplasm undergoes dimerization via “kissing” interactions between palindromic
stem loops. Once linked, a conformational change occurs to expose single-stranded
nucleocapsid (NC) binding motifs (indicated in yellow) which is recognized by the
nucleocapsid portion of the Gag polyprotein and is needed for selecting the gRNA
for packaging. (C) Different viruses form their dimers at different sites; some form
their dimers in the nucleus where the probability of forming homodimers is higher,
whereas other retroviruses associate in the cytoplasm and thus random assortment of
homodimeric and heterodimeric gRNAs occurs. (D) The binding between the Gag
proteins and gRNA dimer can also happen in two sites within the cell. gRNA can
form subassemblies with Gag in the cytoplasm (shown at the top) or may associate at
the plasma membrane (shown at the bottom). (E) Finally two gRNAs are packaged
into the newly budding virus particles. Figure adapted from: Johnson and
Telesnitsky, 2010.
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in an antiparallel direction to initiate “kissing loop” complex that ultimately leads to
a stable dimer formation. The initiation site of gRNA dimerization has been shown
to be different in different retroviruses (reviewed in Johnson & Telesnitsky, 2010;
Jouvenet et al., 2011; Figure 1.10). Consequently, various types of dimers have been
observed in different retroviruses. Viruses that dimerize in the cytoplasm have the
possibility to form both homodimers as well as heterodimers, including HIV-1 and
feline immunodeficiency virus (FIV), whereas viruses undergoing dimerization in
the nucleus usually form homodimers as in the case of MLV and Rous sarcoma virus
(RSV) (reviewed in Johnson & Telesnitsky, 2010; Jouvenet et al., 2011; Figure
1.10).

1.3.9. Retroviral Genomic RNA Packaging
One of the hallmarks of retroviral life cycle is the efficient and specific
packaging of retroviral gRNA as dimers by the assembling virus particles. During
this process, full-length, unspliced gRNA is preferentially packaged, whereas spliced
viral RNA and cellular RNA are generally excluded from being encapsidated into
the nascent virus particles. The packaging specificity results from high-affinity
interactions between NC and a specific sequence at the 5’ end of the viral genome
called the packaging determinant and/or signal (Ψ; reviewed in D'souza & Summers,
2005; Johnson & Telesnitsky, 2010; Lever, 2007).

Determinants of gRNA

dimerization and packaging map to the same 100 to 400 nucleotides at the 5' end of
the gRNA; therefore, it is not surprising that retroviral packaging signal is located
within the dimer linkage structure (DLS) that is formed when two gRNAs dimerize
at their 5’ ends. A number of studies have been undertaken to identify the packaging
determinants of retroviruses, which have shown that packaging sequences are

Figure 1.11: Model depicting specific and selective unspliced genomic RNA packaging among retroviruses.
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Figure 1.11. Model depicting specific and selective unspliced genomic RNA
packaging among retroviruses. Retroviruses specifically and selectively package
their gRNA amongst a pool of other spliced viral and cellular RNAs. The packaging
strategy requires the recognition of the packaging determinants named the packaging
signal (psi or ψ). The location of the packaging signal location is the key for
conferring the specificity of the RNA packaging process since in most of the
retroviruses it is located after the splice donor site (SD). In the spliced RNAs, the
packaging signal is lost during the splicing steps, while in the full length unspliced
genomic RNA, the packaging signal is maintained and only those RNAs containing
the signal can be encapsidated into the virus particle. Figure adapted from Jaballah
thesis, 2010.
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generally present downstream of the major splice donor (mSD). Therefore, a very
simplistic model (Figure 1.11) suggests that the full-length unspliced genomic RNA
is preferentially packaged by virtue of the presence of the packaging determinant
following interaction with NC binding site. On the other hand, in the case of the
spliced RNAs, the packaging sequences are spliced out, thereby excluding them
from encapsidation into the nascent viral particles (Figure 11). Such a model has
been proven true in the case of HIV-1 where the stem loop 2 (SL2) is located in the
region harboring the packaging determinants of HIV-1 and is capable of binding
HIV-1 NC with high affinity. HIV-1 SL2 also contains the mSD; therefore, during
splicing it is deleted leading to its absence in spliced transcripts and rendering them
incapable of binding to NC. This suggests a possible mechanism for discriminating
between spliced and unspliced viral mRNAs (reviewed in D’Souza and Summers,
2005).
The packaging discrimination between spliced and unspliced RNAs in HIV-2
seems to be more complicated as both the spliced and unspliced viral mRNAs
contain the packaging determinants, yet only the unspliced messages are
encapsidated into the virus particle (reviewed in Balvay et al., 2007). HIV-2 has
evolved a distinct strategy to select for the unspliced RNA for packaging by
packaging only those mRNAs that are capable of translating Gag in cis through a
phenomenon called co-translational packaging (Kay and Lever 1999; Griffin et al.,
2001).

Despite the fact that RNA packaging is a universal step in all retroviruses and
the packaging signal required to accomplish this process is found at the 5’ end of the
retroviral gRNA (Figure 1.12), no sequence conservation has been found between
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Figure 1.12: Summary of the packaging and dimerization determinants of a number of different retroviruses.
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Figure 1.12. Summary of the packaging and dimerization determinants of a
number of different retroviruses. Schematic representation of the 5’ end of the
genomic RNA of different retroviruses with the packaging determinants sequences
marked. The packaging signal in almost all retroviruses has been shown to acquire a
higher order secondary structure. The table summarizes and compares the sequences
starting from nucleotide +1 in R to the beginning of gag that have been shown to be
required for optimal packaging of retroviral gRNA as per published data. The
references and other details of the gRNA packaging determinants are provided in the
table below. Figure adapted from Mustafa et al., 2012.
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the packaging signals of different retroviruses. Moreover, it is becoming evident
from the recent cross-packaging studies that switching the packaging sequences
between two different retroviruses that have no primary sequence homology still
maintains efficient packaging (Al Daheri et al., 2009; Al Shamsi et al., 2011). As a
result, it is plausible to assume that gRNA dimerization and packaging process
involves recognition of packaging and dimerization sequences at the secondary
structural level rather than the primary sequence level. Additionally, it has been
observed that the packaging and dimerization sequences of almost all retroviruses
(irrespective of their simple or complex nature) assume higher order structures
comprising of various structural motifs (reviewed in D'souza & Summers, 2005;
Johnson & Telesnitsky, 2010; Lever, 2007; Figure 1.12). One of the characteristic
features of RNA secondary structure of the retroviral packaging signal RNA is the
long range interactions (LRIs) involving sequences of the 5’ and the 3’ end regions,
including sequences in R/U5 that are complementary to a sequence found
downstream in the gag gene.
Owing to the importance of the RNA secondary structures and long-range
base pairings, packaging signal RNA structural models of a number of viruses have
been investigated recently by various approaches such as free energy predictions,
phylogenetic analyses, and biochemical probing, in addition to their subsequent
validation by biological assays. The collective findings are providing new insights
into the structural determinants and molecular mechanisms of retroviral genome
packaging (Kenyon et al., 2008; Rizvi et al., 2010; Jaballah et al., 2010; Kenyon et
al., 2011; Aktar et al., 2013; Aktar et al., 2014).
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1.3.10. Possible Link between Retroviral Genomic RNA Packaging and
Dimerization
Over the years, the retroviral dimerization has been proposed to be closely
related to the viral gRNA packaging, and the dilemma whether dimerization is a prerequest for packaging or they both happen at the same time have been studied
extensively (Hibbert et al., 2004; reviewed in D'souza & summers, 2005; Johnson &
Telestnitsky, 2010; Lever, 2007; Miyazaki et al., 2011; Moore et al., 2009; Paillart et
al., 2004). It has been shown that the packaged RNA remains in the dimeric state,
suggesting that dimerization of the two gRNAs may be a prerequisite for packaging
(Levin et al., 1974; Housset et al., 1993; Hibbert et al., 2004). Consequently, and
not surprisingly, the determinants of gRNA dimerization and packaging map to the
same 100 to 400 nucleotides at the 5' end of the gRNA which have been proposed to
be physically and genetically inseparable (reviewed in D'souza & summers, 2005;
Johnson & Telestnitsky, 2010; Lever, 2007). The understanding of why gRNAs are
packaged as dimers has recently been unveiled in the case of MLV. The NC in
MLV has been shown to specifically bind to unpaired UCUG motifs abundantly
present at the 5’ UTR. However, these motifs in the monomeric gRNA are base
paired and thus the NC cannot have an easy access to them. During dimerization,
interactions between pal helix loops leads to conformational changes in RNA
structural motifs, exposing the high affinity binding sites and making them easily
accessible for NC binding, facilitating the packaging of a dimeric gRNA (D’Souza
& Summers, 2005; Johnson & Telestnitsky, 2010; Figure 1.10).
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1.4.

Genomic RNA Packaging and Dimerization Determinants of

MPMV
MPMV causes an immunodeficiency syndrome in newborn rhesus monkeys
and is a classical type D retrovirus (Bryant et al., 1986; Fine et al., 1975).
Retroviruses that resembles very closely to MPMV and cause acquired
immunodeficiency syndrome (AIDS) in primates have also been characterized and
include simian retrovirus type 1 and type 2 (SRV-1 and SRV-2; Daniel et al., 1984;
Desrosiers et al., 1985; Marx et al., 1984). Among these beta retroviruses, MPMV is
perhaps the most well-investigated in terms of its gRNA packaging and
dimerization. Initially, using MPMV-based retroviral vectors, the first region that
was proposed to be important for its RNA packaging was a 624 nt region
downstream the PBS (Vile et al., 1992). Later, biochemical probing, free-energy
estimations, and phylogenetic analyses were employed to predict the higher order
features of part of this region (up to 130 bp of Gag) which revealed a complex
structure comprising

of eight stem loops (Harrison et al., 1995).

A further

mutational analysis of the 5’ end of MPMV genome revealed that deletion of 61 nt
region upstream of the mSD reduced RNA packaging more than 50%, suggesting
that MPMV core packaging determinants are present upstream of the mSD (Guesdon
et al., 2001).
A more systematic and detailed mutational analysis of the 5’ end of MPMV
genome was later conducted and the mutant RNAs were tested employing a
biologically relevant in vivo packaging and transduction assays. These mutational
analyses revealed that the packaging determinants of MPMV are multipartite and
resides in two distinct regions: region “A” which includes the first 50 nt of UTR and
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Figure 1.13: Comparison of the predicted and the SHAPE (selective 2’ hydroxyl acylation analyzed by primer extension)-validated
structure of MPMV packaging signal RNA.
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Figure 1.13. Comparison of the predicted and the SHAPE (selective 2’ hydroxyl
acylation analyzed by primer extension)-validated structure of MPMV
packaging signal RNA. (A) Structure of MPMV packaging determinants predicted
earlier (Jaballah et al. 2010) by Mfold. Regions that have been shown to be important
for MPMV packaging are highlighted in orange, green, red and blue representing the
primer binding site (PBS) , region A, region B and pal sequence, respectively. Long
range interaction (LRI) -forming sequences are highlighted in purple boxes. (B)
RNA structure of MPMV packaging signal after applying SHAPE-constrains (Reuter
and Mathews 2010). Nucleotides are color coded as per the SHAPE reactivity key.
The SHAPE-validated structure corporates well with the predicted structure except
that in LRI-II the sequence of the X strand gains one extra cytosine at the 3’ end to
become 9 nt in length instead of the predicted 8 nt. In addition, a uridine residue
becomes un-basepaired and forms a bulge in the LRI-II structure. The region used for
the Mfold predictions and the SHAPE analysis included sequences from R up to 120
nt of Gag. Figure adapted from Aktar et al., 2013.
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region “B” that encompasses the last 23 nt of UTR as well as the first 120 nt of Gag
(Schmidt et al., 2003; Jaballah et al., 2010; Figure 1.13). To establish a structurefunction correlation of the effects of the introduced mutations on MPMV RNA
packaging, the region between R and the first 120 nt of Gag was folded and RNA
secondary-structure predictions showed that the 5’ end of MPMV genomic RNA
assumes several stable stem loop structures (Jaballah et al., 2010; Figure 1.13A).
The distinctive features of the predicted structures included U5-Gag long range
interactions (LRIs), a stretch of single-stranded purine (ssPurine)-rich region, and a
distinctive G-C-rich palindromic (pal) stem-loop (Figure 1.13A). Both pal stem-loop
and ssPurine-rich region (or its partial repeat region when predicted to refold as
ssPurines) have been shown to be essential for MPMV RNA packaging (Jaballah, et
al., 2010).
To further validate the predicted RNA secondary structure, a novel chemoenzymatic probing strategy known as Selective 2' Hydroxyl Acylation by Primer
Extension (SHAPE) methodology was employed. SHAPE analysis validated the
overall predicted structure (Jaballah et al. 2010) of the MPMV packaging signal
RNA (Aktar et al., 2013; Figure 1.13B). Finally, a systematic deletion analysis,
minimum free-energy structure predictions, phylogenetic, and in silico modeling
analyses were undertaken to further develop a structure-function relationship of the
various structural motifs of MPMV packaging signal RNA. These analyses revealed
that the 6 nt pal (5’-CGGCCG-3’) within the pal stem-loop functions as MPMV
dimerization initiation site (Aktar et al., 2013).
One of the characteristic feature of the SHAPE-validated secondary structure
of the MPMV packaging signal RNA is the presence of long range interactions
(LRIs: LRI-I and LRI-II; Figure 1.13) between U5 and Gag complimentary
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sequences in the region that have been shown to be important in MPMV RNA
packaging (Schmidt et al., 2003; Jaballah et al., 2010). In silico modeling analysis
of five different MPMV strains predicted both LRIs formation in all the strains
(Aktar et al., 2013; Figure 1.14). Consistent with this the U5 and Gag sequences
involved in the LRIs revealed a high degree of conservation and complimentarily
within strains and maintain a very high degree of complementarity (Aktar et al.,
2013; Figure 1.15). Therefore, it is reasonable to propose that LRIs between U5 and
Gag sequences could potentially play a role in gRNA packaging perhaps by
maintaining the overall MPMV packaging signal RNA secondary structure which
seems to be anchored by complementary and conserved U5 and Gag sequences.
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Boxed regions represent
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SRV2

SRV5

MPMV/6A

Figure 1.14: Mfold predictions of the 5’ end of genomic RNA of five different strains of MPMV
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Figure 1.14. Mfold predictions of the 5’ end of genomic RNA of five different
strains of MPMV showing phylogenetically conserved LRIs involving U5 and Gag
sequences highlighted in red boxes. The accession numbers of MPMV/6A, SRV1,
SRV2, SRV4 and SRV5 are M12349.1(Sonigo et al., 1986), M11841.1 (Power et al.,
1986), AF126467.1 (Marracci et al., 1995), FJ979638.1 (Zao et al., 2010), and
AB611707.1 (Takano et al., 2013), respectively. Figure adopted from Aktar et al.,
2013.
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Figure 1.15: Sequence alignment of 5’ end of genomic RNA from five different
isolates of MPMV using Clustal W.
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UGCCGCGUCGGACUCAGAGGUAAGUGGUGCGCUCGGAAAUGGGACAAGAAUUAAGCCAAC
UCUC-UUUAAUUCCCACCCCCUCCUCCAGGUU-CCUAGUUGUUGAUCCCGCGGGACGGGA
CAUCUGGCGCCCAACGUGGGGCUUGGAUACGAGGGAAUUU-GUGAGGAAGACGGCGCA-C
SRV4
GCCGCCAUUAAACGAGACUUGAUCAGAGCGCUGUCUUGUCUCCAUUUCUUGUGUC
GGACCGGCCGGCGAUUAAAAAG----CGAAAGUACAUUGUCUU-AGCCGCCGCGGGAGCC
UGCCGCGUAGGACCUGAAAGUAAGUGGUGCGCUCGGAUAUGGGGCAGGAAUUAAGCCAGC
297
UGCCGCGUAGGACCUGAAAGUAAGUGGUGCGCUCGGAUAUGGGGCAGGAAUUAAGCCAGC
UCCCAUCCAAUUCCCACUCCCUCCUCCAGGUUUCCUA-CUGUUGGUCCCGCGGGACGGGA
SRV1
GCCACCAUUAAACGAGACUUGAUCAGAACACUGUCUUGUCUCCAUUUCUUGUGUC
CAUUUGGCGCCCAACGUGGCG-UUGGAUACGAGGGAAUUUCGUGAGGAAGACGACGCGGU
gb|M11841.1|SIVRV1CG
UUGCCGGCCCG-GAUUAAAAGAGAAACGAAAGUAAACUUUCUUCGGCCGCCGCGGGAGCC
UGCCGCGUCGGACCUGCAGGUAAGUGUCACGUUCGGAAAUGGGACAAGAAUUAAGCCAGC
281
UGCCGCGUCGGACCUGCAGGUAAGUGUCACGUUCGGAAAUGGGACAAGAAUUAAGCCAGC
U-UCCCUUAAUUCCCACUCCCCUCUCCAGGUCUUCCG-UUGCUAGUCCCGCAGGACGGGA
CACGUGGCGCCCAACGUGGGGCUUGGAUACGGGGGAAUCC-GUGAGGAAGACGACGUG-G
SRV5
--------UAAACGAGACUUGAUCAGAGCCCUGUCUUGUCUCCAUUUCUUGUGUC
dbj|AB611707.1
AAGCCGGCCGAGAAUAAAAG------UGAAAGAAAACUGUUUC-UGCCGCCGCGGGAGCC
UGCCGCGUCGGCAAUAAAGGUAAGCGUUGCGUUCGAAUAUGGGACAAGAAUUAAGCCAAC
286
UGCCGCGUCGGCAAUAAAGGUAAGCGUUGCGUUCGAAUAUGGGACAAGAAUUAAGCCAAC
CACGUGGCGCCCAACGUGGGGCU-GGAUACGAGGGAAUCCUGUGAGGAAGAGAGCGCG-U
gb|AF126467.1
UCUCCCCCAAUUCCCACCCCCUCAUCCAGGUUCUACG-UUGCUGAUCCCGCGGGUCGGGA
SRV2
----CCAUUAAACGAGACUUGAUCAGAGCCCUGUCUUGUCUCCAUUUCUUGUGUC
CLUSTAL 2.1
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gb|M12349.1|SIVMPCG
AUGAACGUUAUGUAGAACAAUUGAAGCAGGCUUUAAAGACACGGGGAGUAAAGGUUAAAU
350
UCGCCGGCCGGCGAUUAAAAG-----UGAAAGUAAACUCUCUU-GGCCGCCGCGGGAACC
CAGUUGGCGCCCAACGUGGGG-CUGGAUACGAGGGAAUUUCGUGAGGAAGACGACGCG-U
UUCCCUUCAAUUCCCACUCCCUCCUCCAGGUU-CCUA-CUGUUGAUCCCGCGGGUCGGGA
MPMV/6A
GCCACCAUUAAAUGAGACUUGAUCAGAACACUGUCUUGUCUCCAUUUCUUGUGUC
gb|M12349.1|SIVMPCG
UGCCGCGUUGGACCUGAAAGUAAGUGUUGCGCUCGGAUAUGGGGCAAGAAUUAAGCCAGC
gb|FJ979638.1
AUGAAAAGUAUAUAGGUCAAUUAAAAGAGGCUUUAAAGACACGAGGAGUAAAGGUCAAAU
351
GGACCGGCCGGCGAUUAAAAAG----CGAAAGUACAUUGUCUU-AGCCGCCGCGGGAGCC
CAUCUGGCGCCCAACGUGGGGCUUGGAUACGAGGGAAUUU-GUGAGGAAGACGGCGCA-C
UCUC-UUUAAUUCCCACCCCCUCCUCCAGGUU-CCUAGUUGUUGAUCCCGCGGGACGGGA
SRV4
GCCGCCAUUAAACGAGACUUGAUCAGAGCGCUGUCUUGUCUCCAUUUCUUGUGUC
gb|FJ979638.1
UGCCGCGUCGGACUCAGAGGUAAGUGGUGCGCUCGGAAAUGGGACAAGAAUUAAGCCAAC
gb|M11841.1|SIVRV1CG
ACGAACGUUAUGUGGAACAAUUAAAACAGGCUUUAAAGACACGGGGAGUAAAGGUUAAAU
357
gb|M11841.1|SIVRV1CG
UUGCCGGCCCG-GAUUAAAAGAGAAACGAAAGUAAACUUUCUUCGGCCGCCGCGGGAGCC
CAUUUGGCGCCCAACGUGGCG-UUGGAUACGAGGGAAUUUCGUGAGGAAGACGACGCGGU
UCCCAUCCAAUUCCCACUCCCUCCUCCAGGUUUCCUA-CUGUUGGUCCCGCGGGACGGGA
SRV1
GCCACCAUUAAACGAGACUUGAUCAGAACACUGUCUUGUCUCCAUUUCUUGUGUC
UGCCGCGUAGGACCUGAAAGUAAGUGGUGCGCUCGGAUAUGGGGCAGGAAUUAAGCCAGC
dbj|AB611707.1 dbj|AB611707.1
AUGACCUUUAUGUAGACCAAUUAAAAAAGGCUUUAAAGGCACGAGGAGUAAAGGUUAAAU
341
AAGCCGGCCGAGAAUAAAAG------UGAAAGAAAACUGUUUC-UGCCGCCGCGGGAGCC
CACGUGGCGCCCAACGUGGGGCUUGGAUACGGGGGAAUCC-GUGAGGAAGACGACGUG-G
U-UCCCUUAAUUCCCACUCCCCUCUCCAGGUCUUCCG-UUGCUAGUCCCGCAGGACGGGA
SRV5
--------UAAACGAGACUUGAUCAGAGCCCUGUCUUGUCUCCAUUUCUUGUGUC
UGCCGCGUCGGACCUGCAGGUAAGUGUCACGUUCGGAAAUGGGACAAGAAUUAAGCCAGC
gb|AF126467.1
AUGAACUUUAUGUAGAACAGUUAAAAAAGGCUCUAAAGACACGGGGAGUAAAGGUUAAGG
346
AACACGGCCGGCAGUCAAAG------UGAAAGAAAAACCUUCC-AGCUGCCGCGGGAACC
CACGUGGCGCCCAACGUGGGGCU-GGAUACGAGGGAAUCCUGUGAGGAAGAGAGCGCG-U
UCUCCCCCAAUUCCCACCCCCUCAUCCAGGUUCUACG-UUGCUGAUCCCGCGGGUCGGGA
SRV2
----CCAUUAAACGAGACUUGAUCAGAGCCCUGUCUUGUCUCCAUUUCUUGUGUC
gb|AF126467.1
UGCCGCGUCGGCAAUAAAGGUAAGCGUUGCGUUCGAAUAUGGGACAAGAAUUAAGCCAAC
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UGCCGCGUUGGACCUGAAAGUAAGUGUUGCGCUCGGAUAUGGGGCAAGAAUUAAGCCAGC
UCGCCGGCCGGCGAUUAAAAG-----UGAAAGUAAACUCUCUU-GGCCGCCGCGGGAACC
CAGUUGGCGCCCAACGUGGGG-CUGGAUACGAGGGAAUUUCGUGAGGAAGACGACGCG-U
UUCCCUUCAAUUCCCACUCCCUCCUCCAGGUU-CCUA-CUGUUGAUCCCGCGGGUCGGGA
UGCCGCGUCGGACUCAGAGGUAAGUGGUGCGCUCGGAAAUGGGACAAGAAUUAAGCCAAC
GGACCGGCCGGCGAUUAAAAAG----CGAAAGUACAUUGUCUU-AGCCGCCGCGGGAGCC
CAUCUGGCGCCCAACGUGGGGCUUGGAUACGAGGGAAUUU-GUGAGGAAGACGGCGCA-C
UCUC-UUUAAUUCCCACCCCCUCCUCCAGGUU-CCUAGUUGUUGAUCCCGCGGGACGGGA
UGCCGCGUAGGACCUGAAAGUAAGUGGUGCGCUCGGAUAUGGGGCAGGAAUUAAGCCAGC
UUGCCGGCCCG-GAUUAAAAGAGAAACGAAAGUAAACUUUCUUCGGCCGCCGCGGGAGCC
CAUUUGGCGCCCAACGUGGCG-UUGGAUACGAGGGAAUUUCGUGAGGAAGACGACGCGGU
UCCCAUCCAAUUCCCACUCCCUCCUCCAGGUUUCCUA-CUGUUGGUCCCGCGGGACGGGA
UGCCGCGUCGGACCUGCAGGUAAGUGUCACGUUCGGAAAUGGGACAAGAAUUAAGCCAGC
AAGCCGGCCGAGAAUAAAAG------UGAAAGAAAACUGUUUC-UGCCGCCGCGGGAGCC
CACGUGGCGCCCAACGUGGGGCUUGGAUACGGGGGAAUCC-GUGAGGAAGACGACGUG-G
U-UCCCUUAAUUCCCACUCCCCUCUCCAGGUCUUCCG-UUGCUAGUCCCGCAGGACGGGA
UGCCGCGUCGGCAAUAAAGGUAAGCGUUGCGUUCGAAUAUGGGACAAGAAUUAAGCCAAC
AACACGGCCGGCAGUCAAAG------UGAAAGAAAAACCUUCC-AGCUGCCGCGGGAACC
CACGUGGCGCCCAACGUGGGGCU-GGAUACGAGGGAAUCCUGUGAGGAAGAGAGCGCG-U
UCUCCCCCAAUUCCCACCCCCUCAUCCAGGUUCUACG-UUGCUGAUCCCGCGGGUCGGGA
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UGCCGCGUUGGACCUGAAAGUAAGUGUUGCGCUCGGAUAUGGGGCAAGAAUUAAGCCAGC
UCGCCGGCCGGCGAUUAAAAG-----UGAAAGUAAACUCUCUU-GGCCGCCGCGGGAACC
CAGUUGGCGCCCAACGUGGGG-CUGGAUACGAGGGAAUUUCGUGAGGAAGACGACGCG-U
UGCCGCGUCGGACUCAGAGGUAAGUGGUGCGCUCGGAAAUGGGACAAGAAUUAAGCCAAC
GGACCGGCCGGCGAUUAAAAAG----CGAAAGUACAUUGUCUU-AGCCGCCGCGGGAGCC
CAUCUGGCGCCCAACGUGGGGCUUGGAUACGAGGGAAUUU-GUGAGGAAGACGGCGCA-C
UGCCGCGUAGGACCUGAAAGUAAGUGGUGCGCUCGGAUAUGGGGCAGGAAUUAAGCCAGC
UUGCCGGCCCG-GAUUAAAAGAGAAACGAAAGUAAACUUUCUUCGGCCGCCGCGGGAGCC
CAUUUGGCGCCCAACGUGGCG-UUGGAUACGAGGGAAUUUCGUGAGGAAGACGACGCGGU
UGCCGCGUCGGACCUGCAGGUAAGUGUCACGUUCGGAAAUGGGACAAGAAUUAAGCCAGC
AAGCCGGCCGAGAAUAAAAG------UGAAAGAAAACUGUUUC-UGCCGCCGCGGGAGCC
CACGUGGCGCCCAACGUGGGGCUUGGAUACGGGGGAAUCC-GUGAGGAAGACGACGUG-G
UGCCGCGUCGGCAAUAAAGGUAAGCGUUGCGUUCGAAUAUGGGACAAGAAUUAAGCCAAC
AACACGGCCGGCAGUCAAAG------UGAAAGAAAAACCUUCC-AGCUGCCGCGGGAACC
CACGUGGCGCCCAACGUGGGGCU-GGAUACGAGGGAAUCCUGUGAGGAAGAGAGCGCG-U
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UGCCGCGUUGGACCUGAAAGUAAGUGUUGCGCUCGGAUAUGGGGCAAGAAUUAAGCCAGC
UCGCCGGCCGGCGAUUAAAAG-----UGAAAGUAAACUCUCUU-GGCCGCCGCGGGAACC
UGCCGCGUCGGACUCAGAGGUAAGUGGUGCGCUCGGAAAUGGGACAAGAAUUAAGCCAAC
GGACCGGCCGGCGAUUAAAAAG----CGAAAGUACAUUGUCUU-AGCCGCCGCGGGAGCC
UGCCGCGUAGGACCUGAAAGUAAGUGGUGCGCUCGGAUAUGGGGCAGGAAUUAAGCCAGC
UUGCCGGCCCG-GAUUAAAAGAGAAACGAAAGUAAACUUUCUUCGGCCGCCGCGGGAGCC
UGCCGCGUCGGACCUGCAGGUAAGUGUCACGUUCGGAAAUGGGACAAGAAUUAAGCCAGC
AAGCCGGCCGAGAAUAAAAG------UGAAAGAAAACUGUUUC-UGCCGCCGCGGGAGCC
UGCCGCGUCGGCAAUAAAGGUAAGCGUUGCGUUCGAAUAUGGGACAAGAAUUAAGCCAAC
AACACGGCCGGCAGUCAAAG------UGAAAGAAAAACCUUCC-AGCUGCCGCGGGAACC
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Figure 1.15. Sequence alignment of 5’ end of genomic RNA from five different
isolates of MPMV using Clustal W.

The alignment reveals a high degree of

conservation of the sequences involved in the formation of the two LRIs (sequences
in the boxes). Even though those sequences show a slight variation, yet they still
maintain a high degree of complementarity. The U5/Gag sequences involved in the
formation of LRI-I are highlighted in red, whereas the sequences forming LRI-II are
highlighted in blue. The accession numbers of MPMV/6A, SRV1, SRV2, SRV4 and
SRV5 are M12349.1(Sonigo et al., 1986), M11841.1 (Power et al., 1986),
AF126467.1 (Marracci et al., 1995), FJ979638.1 (Zao et al., 2010), and AB611707.1
(Takano et al., 2013), respectively. Figure adapted from Aktar et al., 2013.
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1.5.

Objectives
Our predicted and SHAPE-validated structures of MPMV gRNA have shown

conserved LRIs between the U5 and Gag complimentary sequences in a region that
have been shown to be crucial for MPMV gRNA packaging. In addition, several
studies from a number of retroviruses have reported the existence of such LRIs
which have been found to be crucial for retroviral gRNA packaging. Therefore, we
hypothesize that the RNA secondary structures of the MPMV appears to be anchored
by complementary sequences in the U5 region and within the Gag open
reading frame, providing stability to the overall secondary structure to MPMV
packaging signal RNA. We further hypothesize that the U5 and gag complementary
sequences involved in LRIs could either function at the primary sequence level or at
the structure level during MPMV RNA packaging process. Therefore, in this thesis,
we tested the following:
1. Ascertain the existence as well as the biological significance of LRIs in MPMV
and packaging signal RNA sequences required in cis for gRNA packaging
2. Ascertain whether the complimentary U5-Gag sequences involved in maintaining
LRIs function at the primary sequence level or the structural level (or both)
during gRNA packaging
3. Establish structure-function relationship during the MPMV gRNA packaging
process by correlating the biological results with the structural predictions of the
LRI mutants
4. Establish the role of Gag sequences other than those involved in U5-Gag LRIs
during the MPMV gRNA packaging process.
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Chapter 2: Materials & Methods
2.1. Genome Nucleotides Numbering System
The MPMV nucleotide numbering system refers to the genome sequence
deposited in the Genbank (accession number M12349) by Sonigo et al. (1986).

2.2.

Plasmid Construction:

2.2.1. MPMV Packaging Construct:
The packaging construct is the plasmid that provides the viral structural
proteins into which retroviral gRNA is packaged. In the case of MPMV, TR301
plays this role and has been described earlier (Browning et al., 2001). In brief,
TR301 plasmid expresses the MPMV gag/pol genes under the transcriptional control
of the human cytomegalovirus (hCMV) intron A promoter/enhancer. In TR301,
MPMV CTE has been cloned between pol termination codon and the bovine growth
hormone (BGH) poly A sequences to ensure proper nuclear export of the unspliced
gag/pol mRNA (Figure 2.1).

2.2.2. MPMV Transfer Vector:
The MPMV sub-genomic transfer vector, SJ2, has been described previously
(Jaballah et al., 2010) and harbors all the required cis-acting sequences for
transcription, polyadenylation, reverse transcription, integration, dimerization, and
packaging (Figure 2.1). In addition to these cis-acting sequences, SJ2 also expresses
hygromycin B phosphotransferase gene from an internal simian virus 40 early
promoter (SV-Hygr ) that is is used as the selectable marker. The overall size of SJ2

MD.G CMV VSV-G env

gag

PBS

U3 R U5

TR301 CMV

SJ2



MPMV U3
R U5
Genome
PBS


pol

7181

CTE

Poly A

SV hygr env

1174

Poly A

pol

gag

gag

1174

8557

U3 R U5

8557
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U3 R U5
CTE

env
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Figure 2.1: Schematic representation of MPMV genome, its sub-genomic transfer vector, the packaging construct and the envelope
expression plasmid.
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Figure 2.1.

Schematic representation of MPMV genome, its sub-genomic

transfer vector, the packaging construct and the envelope expression plasmid.
The wild type sub-genomic transfer vector, SJ2, contains a deletion in MPMV
sequences between nt 1174 and 7181.

This region has been replaced with

hygromycin resistance gene expressed from an internal simian virus 40 promoter
(SV-hygr cassette). This transfer vector was used to introduce mutations in the LRII, LRI-II and other sequences. TR301 is the packaging construct that expresses
MPMV Gag/Pol proteins. MD.G plasmid expresses envelope glycoproteins G from
vesicular stomatitis virus (VSV-G). , packaging signal; CTE, constitutive transport
element; SV, Simian virus 40 promoter; hygr, hygromycin resistance gene; CMV,
human cytomegalovirus promoter; Poly A, polyadenylation sequences.
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is approximately 6 kb and at its 5’ end contain sequences upto 283 nt of Gag (nt
1174) while at the 3’ end, it contains sequences from MPMV nucleotide 7181 until
the end of MPMV genome (nt 8557).

2.2.3. Envelope Expression Plasmid:
The vesicular stomatitis virus glycoprotein G (VSV-G) expression vector
MD.G was used to psuedotype the virus particle produced following transfection.
This enables these pseudotyped viruses to infect a number of target cells since
receptors for VSV-G are present on many cell types (Figure 2.1). Such pseudotyped
particles allowed studying the effect of the mutations on RNA packaging and mutant
transfer vector RNA propagation. MD.G has been previously described (Naldini et
al., 1996) and was kindly provided by Dr. Dider Trono (Salk Institute,La Jolla, CA).

2.2.4. Transfer Vectors Containing Different Mutations:
To validate the existence and biological significance of the U5-Gag LRIs, a
series of mutations were introduced into them. The first series of mutations included
deletion of the U5 sequence, the Gag sequence, or both. Mutations were introduced
by designing customized primers that can be used in a splice overlap extension PCR
(Gibbs et al., 1994) using SJ2 transfer vector as the template DNA as has been
represented schematically in figure 2.2 and described previously (Jaballah et al.,
2010). Briefly, two rounds of PCR amplifications were performed and each round
required a different set of primers. In the first round, the customized primers that
were designed flanking the region of mutation were used in two separate PCR
reactions, (A) and (B). PCR (A) was performed using the universal outer forward
(sense; S) primer OTR787 (5’ccctcgagTGTCCGGAGCCGTGCTGCCCG 3’; first 2

U3 R U5

U3 R U5

gag
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env
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XhoI

Δ region
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to product A and B as templates
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Product A
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XhoI

CTE

Product B
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Figure 2.2: Schematic illustration of the splice overlap extension (SOE) PCR strategy used to introduce mutations.
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Figure 2.2. Schematic illustration of the splice overlap extension (SOE) PCR
strategy used to introduce mutations. In the first round of PCR, two separate PCR
reactions were performed (PCR-A and PCR-B) where each has an outer primer that
amplifies either the 5’ end or 3’ end regions of the MPMV sequences and another
internal primer that is specific to the mutated sequence. Both inner sense (S) and
antisense (AS) primers that were employed in PCRs (B) and (A), respectively, were
customized in a way that the resulting PCR products from these two separate
reactions (PCR A and PCR B) should have overlapping complementary sequences.
The presence of these complementary sequences in PCR products A and B allowed
them to anneal in round 2 PCR when performed using outer S and AS primers,
generating a final product harboring the deletion introduced. Following round 2
PCR, the final product in addition to containing the desired mutation also acquired
flanking distinctive endonuclease restriction sites, namely BamHI at the 5'-end and
XhoI at the 3'-end of the product that was designed to be used to clone the desired
mutations. , packaging signal; CTE, constitutive transport element; SV, Simian
virus 40 promoter; hygr, hygromycin resistance gene. nucleotides (nts) are dummies
followed by XhoI site and MPMV 5’ LTR sequences spanning the region between
nts 397-417 shown in upper case; sequences shown in lowercase were incorporated
for cloning purpose) along with the inner reverse (antisense; AS) primer that varied
depending upon the mutation introduced. In PCR (B), the AS outer primer OTR788
(5’cccggatccTTCTTTCTTATCTATCAATTCTTTAATTAAG 3’; first 3 nt are
dummies followed by BamHI site and MPMV Gag sequences spanning the region
between nts 1171-1141 shown in upper case; sequences shown in lowercase were
incorporated for cloning purposes) was used along with the inner S primer which
also varied depending upon the mutations introduced.
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Both inner S and AS primers that were employed in PCRs (A) and (B),
respectively, were customized in a way that the resulting PCR products from these
two separate reactions (PCR A and PCR B) would have overlapping complementary
sequences. The presence of these complementary sequences in PCR products A and
B allowed them to anneal in round 2 PCR when performed using outer S and AS
primers (OTR787/OTR788), generating a final product harboring the mutation
introduced. Following round 2 PCR, the final product, in addition to containing the
desired mutation, should also acquire flanking distinctive endonuclease restriction
sites namely: BamHI at the 5'-end and XhoI at the 3'-end of the product (Figure 2.2).
The reason of introducing these single cutters (BamHI and XhoI) was to allow their
cloning in a directed manner into the SJ2 vector backbone creating the mutant
transfer vectors. Utilizing this methodology, various mutations were introduced into
the SJ2 backbone and the mutations were verified by DNA sequencing (Tables 1;2).
The inner S and AS oligos that were designed and synthesized for
introducing the specific mutations into SJ2 are described in the following sections
along with the nature of the mutation introduced. In these oligos the underlined
nucleotides represent complementary sequences of the tail that will not anneal to the
template in the first round PCR but will allow the products from PCR A and PCR B
to anneal during round 2 PCR (Figure 2.2).

Substitution of the upper strand X-I (U5) of 13 nt LRI-I with heterologous sequence

Wild Type predicted sequence
Substitution of upper 8nt X-II (U5) LRI-II with heterologous sequence
Substitution of upper 8 nt X-II (U5) of LRI-II with the lower 8 nt Y-II (Gag) of LRI-II sequence

∆
∆
3’ UGAGGGGCACAGA 5’

Y-II (Gag)
3’ GAACGGGG 5’
3’ GAACGGGG 5’
3’ GAACGGGG 5’
3’ cuuguucc 5’
3’ ccuuguuc 5’

3' GAACGGGG 5'
3' GAACGGGG 5'
3' GAACGGGG 5'

3' uccuccucc 5'

5’ AUUUCUUGUGUCU 3’

∆

5’ aucucuuauauau 3’

5’ aucucuuauauau 3’

X-II (U5)

5’ CUUGUUCC 3’**

5’ agauagag 3’

5’ggggcaag 3’

5’ CUUGUUCC 3’

5’ ggggcaag 3’

5' CUUGUUCCC 3‘***

∆

5' aggaggagg 3'

5' aggaggagg 3'

RK4

RK5

RK6

RK7

Clone Name

SJ2

RK8

RK9

RK10

RK11

SJ2

RK12

RK13

RK14

3’ uagagaauauaua 5’

Double deletion of 13 nt upper X-I (U5) and lower Y-I (Gag) strands of LRI-I

3’ UGAGGGGCACAGA 5’

∆

RK3

Substitution of lower 8 nt Y-II (Gag) of LRI-II with complimentary heterologous sequence to RK13

Substitution of upper 9 nt X-II (U5) of LRI-II with heterologous sequence

Deletion of upper 9 nt X-II (U5) of LRI-II

Wild Type SHAPE-validated sequence

Substitution of upper 8 nt X-II (U5) of LRI-II with lower 8 nt Y-II (Gag) of LRI-II sequence complimentary
to RK10

Substitution of lower 8 nt Y-II (Gag) of LRI-II with upper 8 nt X-II (U5) of LRI-II sequence

Description of the Mutation

Substitution of the lower Y-I (Gag) 13 nt LRI with complimentary heterologous sequence to RK6

Deletion of the lower Y-I (Gag)13 nt of LRI-I

Deletion of the upper X-I (U5) 13 nt of LRI-I

Substitution of ‘U’ in the upper strand X-I and II (U5) of both LRIs with ‘C’

3’ UGAGGGGCACAGA 5’

5’ acuccccgugucu 3’*

RK2

Substitution of ‘U’ in the upper strand X-I (U5) of 13nt LRI-I with ‘C’

3’ UGAGGGGCACAGA 5’

5’ acuccccgugucu 3’

RK1

Description of the Mutation
Wild Type SHAPE-validated sequence

5’ AUUUCUUGUGUCU 3’

SJ2

Y-I (Gag)
3’ UGAGGGGCACAGA 5’

X-I (U5)

Clone Name

Table 1: List of deletion/substitution mutations that have been introduced in sequences involved in the formation of LRI-I and LRI-II
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Description of the Mutation
Deletion of 33 nt of SL3
Deletion of 30 nt of Gag SL2

Deletion of 39 nt of Gag SL1
Double Deletion of SL3 and Gag SL1
Double Deletion of SL3 and Gag SL2
Triple Deletion of SL3, Gag SL1 and Gag SL2

Clone Name

RK15

RK16

RK17

RK18

RK19

RK20

Table 2. Table outlining the deletion mutations introduced into the Gag sequences
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2.2.5. Transfer Vectors Containing Substitutions of Uridine (U) in G-U base
pairs with Cytosine (C) in the Upper (X-I and X-II) sequence of both LRI-I and
LRI-II
RK1: All Us involved in wobble base-pairing within the U5 sequence of the LRI-I
were substituted with Cs in order to make a more stable LRI-I using the following
primers:
OTR1157: S; 5’ ACT CCC CGT GTC TCT TGT TCC CTT CAA TTC CCA C3’,
MPMV: 678-698nt.
OTR1158: AS; 5’ GAA CAA GAG ACA CGG GGA GTG GAG ACA AGA CAG
TGT TCT GA 3’; MPMV: 684-643nt.

RK2: All Us involved in wobble base-pairing within the U5 sequences of both LRI-I
and LRI-II were substituted with Cs in order to make more stable LRIs using the
following primers:
OTR1159: S; 5’ ACT CCC CGT GTC TCT TGC CCC CTT CAA TTC CCA CTC
CCT CC 3’; MPMV: 686-705 nt.
OTR1160: AS; 5’ GAA GGG GGC AAG AGA CAC GGG GAG TGG AGA CAA
GAC AGT GTT CTG 3’; MPMV: 664-645 nt.

2.2.6. Transfer Vectors Containing Deletions of Sequences Involved in U5-Gag
LRI-I
RK3: Deletion of U5 sequence X-I (13 nt) of the LRI-I through SOE PCR using
following primers:
OTR1190: S; 5’ CTT GTT CCC TTC AAT TCC CAC 3’, MPMV: 678nt-698nt.
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OTR1191: AS; 5’ GGA ATT GAA GGG AAC AAG GGA GAC AAG ACA GTG
TTC TGA T 3’ MPMV: 695-678 nt Δ 664-642 nt.

RK4: Deletion of Gag sequence Y-I (13 nt) of the LRI-I using following primers:
OTR1192: S; 5’ AAA GGT TAA ATA TGC TGA TCT TTT G 3’; MPMV: 961985 nt.
OTR1193: AS; 5’ GAT CAG CAT ATT TAA CCT TTT TAA AGC CTG CTT
CAA TTG TTC TA 3’; MPMV: 980-961 nt Δ 946-924 nt.

RK5: Deletion of both complementary sequences involved in the formation of U5Gag LRI-I using the DNA of RK4 as template and OTR1190 and OTR1191
described above.

2.2.7. Transfer Vectors Containing Substitutions of Sequences Involved in U5Gag LRI-I
RK6: Substitution of U5 sequence X-I (13 nt) of the LRI-I with heterologous
sequence (5’-AUCUCUUAUAUAU-3’) using the following primers:
OTR 1153: S; 5’ ATC TCT TAT ATA TCT TGT TCC CTT CAA TTC CCA C 3’;
MPMV: 678-698nt.
OTR 1154: AS; 5’ GAA CAA GAT ATA TAA GAG ATG GAG ACA AGA CAG
TGT TCT G 3’; MPMV: 684-645 nt.
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RK7: Substitution of Gag sequence Y-I (13 nt) of the LRI-I with a heterologous
sequence (5’-ATATATAAGAGAT -3’) complementary to the sequence introduced
in RK6 to restore artificial complementarity using the following primers:
OTR1155: S; 5’ ATA TAT AAG AGA TAA AGG TTA AAT ATG CTG ATC TTT
TG 3’; MPMV: 961-985 nt.
OTR1156: AS; 5’ CCT TTA TCT CTT ATA TAT TTA AAG CCT GCT TCA ATT
GTT C 3’; MPMV: 965-926 nt.

2.2.8. Transfer Vectors Containing Substitutions of Sequences (8 nucleotides of
the predicted structure) Involved in U5-Gag LRI-II
RK8: Substitution of U5 sequence X-II (8 nt of the predicted structure) of the LRI-II
with heterologous sequence (5’-AGA UAG AG-3’) using the following primers:
OTR1095: S; 5’ AGA TAG AGC TTC AAT TCC CAC TCC CTC C 3’; MPMV
686-705 nt.
OTR1096: AS; 5’ GAA TTG AAG CTC TAT CTA GAC ACA AGA AAT GGA
GAC AAG 3’; MPMV 694-652 nt.

RK9: Substitution of U5 sequence X-II (8 nt) of the LRI-II with its complementary
Gag sequence Y-II (5’-GGG GCA AG-3’) to disrupt the complementarity and
thereby LRI-II using following primers:
OTR1093: S; 5' GGG GCA AGC TTC AAT TCC CAC TCC CTC C 3', MPMV:
686-705 nt.
OTR 1094: AS; 5' GAA TTG AAG CTT GCC CCA GAC ACA AGA AAT GGA
GAC AAG 3'; MPMV: 694-656 nt.
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RK10: Substitution of Gag sequence Y-II (8 nt) of the LRI-II with U5 sequence
maintaining 3’ to 5’ orientation thereby disrupting the complementarity using the
following primers:
OTR1099: S; 5’ CCT TGT TCA ATT AAG CCA GCA TGA ACG TTA TG 3’ ,
MPMV: 900-924 nt.
OTR1100: AS; 5’GCT TAA TTG AAC AAG GAT ATC CGA GCG CAA CAC
TTA C 3’, MPMV: 891-871 nt.

RK11: Substitution of Gag sequence Y-II (8 nt) of the LRI-II with its
complementary U5 sequence X-II (5’-CUU GUUCC-3’) using RK9 (in which U5
sequence X-II has already been substituted with its complementary Gag sequence
Y-II (5’-GGG GCA AG-3’) to disrupt the complementarity as template DNA during
PCR creating a double mutant to restore complementarity (by flipping the sequence)
in LRI-II using the following primers:
OTR1101: S; 5’CTT GTT CC A ATT AAG CCA GCA TGA ACG TTA TG 3’;
MPMV: 900-923 nt.
OTR1102: AS; 5’GCT TAA TT G GAA CAA GAT ATC CGA GCG CAA CAC
TTA C 3'; MPMV: 907-900 nt 5'-GGA ACA G 3’ 891-872 nt.

2.2.9. Transfer Vectors Containing Deletions of Sequences (SHAPE validated 9
nucleotides) Involved in U5-Gag LRI-II
RK12: Deletion of U5 sequence X-II (SHAPE validated 9 nt) of the LRI-II through
SOE PCR using the following primers:
OTR1188: S; 5’ TTC AAT TCC CAC TCC CTC CTC3’, MPMV: 687-707 nt.
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OTR1189: AS; 5’ GAG GGA GTG GGA ATT GAA AGA CAC AAG AAA TGG
AGA CAA G 3’ , MPMV: 704-687 nt and 678-669nt.

2.2.10. Transfer Vectors Containing Substitutions of Sequences (SHAPE
validated 9 nucleotides) Involved in U5-Gag LRI-II
RK13: substitution of U5 sequence X-II (9 nt of the SHAPE validated structure) of
the LRI-II with heterologous sequence (5’-AGG AGG AGG-3’) using following
primers:
OTR1178: S; 5’AGG AGG AGG TTC AAT TCC CAC TCC CTC CT 3’; MPMV:
687-707 nt.
OTR1179: AS; 5’ GAA CCT CCT CCT AGA CAC AAG AAA TGG AGA CAA G
3’; MPMV: 677-657 nt.

RK14: Substitution of Gag sequence Y-II (9 nt of the SHAPE validated structure) of
the LRI-II with heterologous sequence complementary with the one introduced in
RK13 using RK13 DNA as template and the following primers:
OTR1180: S; 5’ CCT CCT CCT AAT TAA GCC AGC ATG AAC GTT A 3’;
MPMV: 900-920 nt.
OTR1181: AS; 5’ CTT AAT TAG GAG GAG GAT ATC CGA GCG CAA CAC
TTA C3’; MPMV: 906-871 nt.

2.2.11 Transfer Vectors Containing Deletions of Sequences Involved in
Forming Stem Loops at the 3’ end of the SHAPE Validated Structure
RK15: Deletion of the 33 nucleotides involved in forming the lower part of stem
loop 3 (SL3) using the following primers:
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OTR1079: S; 5’ CTC TCG AAA GTA AGT GTT GCG CTC GG 3’, MPMV: 8298-33 and from 867-886 nt.
OTR1080: AS; 5’ CTT TCG AGA GTT TAC TTT CAC TTT TAA TC 3’, MPMV:
871- 867 and from 833-810 nt.
RK16: Deletion of the 30 nucleotides of Gag sequences involved in forming Gag
stem loop 2 (complete deletion of Gag SL2) using the following primers:
OTR1085: S; 5’ GCT GAT ACT TGT CCT TGG TTT CCG C 3’; MPMV: 974-978
and from 1009-1028 nt.
OTR1086: AS; 5’ CAA GTA TCA GCA TAT TTA ACC TTT ACT CC 3’;
MPMV: 1014-1009 and from 978-956 nt.

RK17: Deletion of the 39 nucleotides of Gag sequences involved in forming Gag
stem loop 1 (complete deletion of Gag SL1) using the following primers:
OTR1194: S; 5’ TTA AAG ACA CGG GGA GTA AAG G 3’; MPMV: 944-965 nt.
OTR1195: AS; 5’ TAC TCC CCG TGT CTT TAA TAA TTC TTG CCC CAT
ATC CGA G 3’; MPMV: 961-944nt and from 904-883nt.

RK18: Simultaneous deletion of sequences involved in forming the lower part of
stem loop 3 (SL3) and Gag stem loop 1 (Gag SL1) using RK15 DNA as template
and the following primers:
OTR1194: S; 5’ TTA AAG ACA CGG GGA GTA AAG G 3’; MPMV: 944-965 nt.
OTR1195: AS; 5’ TAC TCC CCG TGT CTT TAA TAA TTC TTG CCC CAT
ATC CGA G 3’; MPMV: 961-944 nt and from 904-883 nt.
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RK19: Simultaneous deletion of the sequences involved in forming the lower part of
stem loop 3 (SL3) and Gag stem loop 2 (Gag SL2) using RK15 DNA as template
and the following primers:
OTR1196: S; 5’ TAC TTG TCC TTG GTT TCC GCA A 3’; MPMV: 1009-1030 nt.
OTR1197: AS; 5’ GGA AAC CAA GGA CAA GTA TCA GCA TAT TTA ACC
TTT ACT CCC 3’; MPMV: 1026-1009 nt and from 978-955 nt.

RK20: Simultaneous deletion of the sequences involved in forming the lower part of
stem loop 3 (SL3), Gag stem loop 1 (Gag SL1), and Gag stem loop 2 (Gag SL2)
using RK19 DNA as template and the following primers:
OTR1194: S; 5’ TTA AAG ACA CGG GGA GTA AAG G 3’; MPMV: 944-965 nt.
OTR1195: AS; 5’ TAC TCC CCG TGT CTT TAA TAA TTC TTG CCC CAT
ATC CGA G 3’; MPMV: 961-944 nt and from 904-883 nt.

2.3.

Three-plasmid trans-complementation assay
The U5-Gag LRI mutants were tested for both packaging and propagation

employing a previously transcribed three plasmid trans-complementation assay
developed by our group (Figure 2.3; Browning et al., 2001; Schmidt et al., 2003;
Jaballah et al., 2010) to establish the biological significance of U5-Gag LRIs. As the
name indicates, this assay utilizes three different plasmids to establish reliable
experimental conditions to monitor the effects of U5-Gag LRIs mutants on both
MPMV gRNA packaging and propagation. The three plasmids that were used in this
assay included: 1) wild type SJ2 or the mutant transfer vector which contains

C



Nuclear

B

pol
Poly(A)n

CTE

Poly(A)n







X

X

X

Transfect producer cells

env

gag

RNA
Fractionation

Gag/Pol
Packaging CMV
Construct
(TR301)
Env
CMV
Expression
Construct
(MD.G)

Cytoplasmic

Real time
PCR

A

Transfer
Vector
(SJ2)



Select for
hygromycin
resistant
colonies

X

Virus
isolation

Real time
PCR

Target Cells

D



Infection



Make virus
particles

Makes packageable
RNA

Figure 2.3: Illustration of the 3-plasmid trans complementation assay.
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Figure 2.3. Illustration of the 3-plasmid trans complementation assay. A. Design o f the three
plasmids that were transfected to produce virus particles. B. Cartoon depicting a 293T cell that has
been co-transfected with the 3 plasmids to produce the replication-defective but infectious virus
particles. Inside the cell, virus particles are made by Gag/pol proteins produced by the expression
plasmid (TR301). The packageble RNA is produced by the MPMV wild type transfer vector (SJ2),
while the vesicular stomatitis envelope expression construct (MD.G) produces the necessary envelope
glycoprotein to pseudotype the virus particles and infect the target cells. The only RNA that can be
packaged into the budding virus particles is the one that is generated from the transfer vector RNA
since only that RNA contains an intact packaging signal. C. The transfected producer cells are
processed and fractionated into nuclear and cytoplasmic fractions. The cytoplasmic fractions are used
to study the cytoplasmic expression of the gRNA in the cells by RT-PCR followed by real time PCR.
D. Once transfected, the 293T cell produce virus particles containing the packaged transfer vector
RNA (SJ2). These particles are used to isolate the packaged viral RNA and quantitate relative RNA
packaging in different mutants by RT-PCR followed by real time PCR. In addition, these particles
are also used to infect target cells to study RNA propagation. After infection, target cells were
selected with media containing hygromycin B antibiotic so that only those cells in which there had
been a successful infection allowing them to express hygromycin resistance gene would survive. The
number of the resulting hygromycin resistant colonies (colony forming unit/ml; CFU/ml) directly
correlates with the amount of RNA packaged unless a step in the viral life cycle following RNA
packaging has been affected. The virions produced by the 293T cells are restricted to one round of
replication inside the target cells as they contain only the transfer vector RNA as their genome
restricting the re-infection of the target cells, making the assay quantitative and sensitive. RNAs that
cannot be packaged since they 1) do not carry packaging signal on themselves or 2) the cells do not
carry RNA to produce viral proteins for their encapsidation. Figure partly adapted from D'Souza and
Summers, 2005.
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minimum cis-acting sequences required for RNA packaging, reverse transcription,
and integration and functions as substrate to produce packageble RN, 2) packaging
construct TR301 that expresses the MPMV the structural and enzymatic proteins,
and 3) vesicular stomatitis envelope glycoprotein expression plasmid MD.G to
pseudotype the viral particles produced containing the packaged RNA.

An

additional plasmid pGL3C (Promega, Madison, WI) which expresses the firefly
luciferase gene was also added to the DNA cocktail to monitor the transfection
efficiencies.

2.3.1. Transfection of Producer Cells
The producer 293T cells were seeded in six-well plates at a density of 4 ×
105 cells per well and maintained at 370 C in Dulbecco’s modified Eagle’s medium
(DMEM) supplemented with 10% FBS from Hyclone (Logan, UT) a day prior to
transfection and maintained in a humidified incubator with a constant supply of 5%
CO2. After approximately 16 hours of seeding the cells, media was changed 24 hours before performing the transfections. Calcium phosphate transfections were
performed by preparing a DNA cocktail with a total of 6μg DNA (2 μg of transfer
vector + 2 μg of the envelope expression vector MD.G + 2 μg of the packaging
construct TR301) + 250 ng of the pGL3C vector expressing the firefly luciferase
gene.

The DNA cocktail was prepared in a buffer containing 250 mM CaCl2,

150 mM NaCl, 10 mM Tris-Cl, pH 7.4, and 1 mM EDTA. In order to form the
calcium phosphate precipitate, a 2X transfection buffer (50 mM HEPES, 180 mM
NaCl, 4 mM sodium phosphate, pH 7.0) was added drop-wise to the DNA cocktail
while bubbling for approximately 2 minutes including, a 15 second vortex to
increase the aeration in the tube. Finally, the precipitates were allowed to form
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during a 30 minute incubation period at room temperature. The resulting precipitate
was added drop-wise in a circular motion to the 293T plates and incubated for
4 hours at 370 C. At the end of the 4 hours incubation, transfected cells were washed
twice, first wash with the media in the plate itself and the second round with
phosphate-buffered saline (PBS). Lastly, 3 ml of fresh medium was added to each
well and incubated overnight. The next day, the old media was removed and 1.5 ml
fresh medium was added to each well. Lowering the media helps in concentrating
the virus particles in the producer cell supernatant. Briefly, approximately 60 hours
following transfection, pseudotyped virus particles produced were used to monitor
transfer vector RNA packaging and propagation (Figure 2.3).

To monitor the

efficiency of RNA packaging, viral RNA was isolated from the virions produced in
the culture supernatants and quantitated using real time quantitative PCR (qPCR;
described in detail below).

2.3.2. Infection of Target Cells
Transfer vector RNA propagation of the packaged RNA was assessed by
infecting HeLa T4 target cells with the virions produced by the 293T producer cells
(Figure 2.3). RNA propagation was monitored by the successful transduction of the
target cells by the hygromycin resistance gene present on the packaged transfer
vector RNA. Briefly, HeLa T4 cells were maintained in DMEM supplemented with
7% calf serum from Hyclone (Logan, UT). They were seeded approximately 16
hours prior to infection at a density of 4x105 cells/60mm plate. Supernatants from
the transfected 293T producer cells were harvested approximately 60 hours post
transfection, subjected to low speed centrifugation (2500 rpm) for 10 minutes to
remove cellular debris and used to infect Hela T4 cells using DEAE-dextran as
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described earlier (Browning et al., 2001). The cleared viral supernatant was also
used to isolate virus particles to extract virion RNA (described in detail in section
2.3.5). Approximately 48 hours post infection, infected cultures were selected with
media containing 200 µg/ml hygromycin B antibiotic for about 10-12 days following
which hygromycin resistant colonies were stained with 0.5% crystal violet dye in
50% methanol as described earlier (Browning et al., 2001).

The number of

hygromycin resistant colonies represented as colony forming units per milliliter
(CFU/ml) are directly proportional to the propagation efficiency of packaged transfer
vector RNA (Browning et al., 2001). The colony counts were normalized to the
transfection efficiency of different cultures as measured by luciferase expression
(described in detail in section 2.3.1).

2.3.3. Luciferase Assay and the Transfection Efficiency:
Following transfection of the producer cells transfection efficiencies in the
cultures were monitored by the Dual-luciferase Reporter Assay (Promega, Madison,
WI).

Briefly, after collecting the culture supernatants, 1 ml of DMEM

containing10% FBS and 1 ml of cold PBS was added to each well and the cells were
removed without trypsinization. Harvested cells were then washed once in 5 ml cold
PBS, centrifuged at 1500 rpm for 5 min, and the resulting cellular pellet was
resuspended in 1 ml of cold PBS. Next, 100 µl of cells (1/10th the volume) were
pelleted and resuspended with 100 µl of 1X Passive Lysis Buffer, PLB, (Promega,
Madison, WI). To prepare the cell lysate, resuspended cells were subjected to three
freeze/thaw cycles of (each comprising of 2 minutes in dry ice-ethanol bath and 2
minutes at 370 C water bath) followed by microcentrifugation at 40 C for 5 minutes at
13k rpm to pellet down cellular debris. Clarified lysates were transferred to new
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eppendorf tubes and were used in the Dual-reporter Luciferase Assay. For every 2µl
lysate, 25µl of the Luciferase Assay Reagent II (LARII), was added, mixed by
tapping gently, and the readings were taken in the Turner TD-20e Luminometer
(Turner Design, Inc. Sunnyvale, CA) using a 5 seconds delay and 20 seconds
integration time. In order to determine protein concentrations, the same cell lysates
were tested in the Bradford Bio-Rad Protein Assay (BioRad, Hercules, CA) against a
standard curve that was prepared from known concentrations of bovine serum
albumin (BSA). The luciferase readings were then normalized to protein values in
order to determine relative transfection efficiencies represented as luciferase activity
per µg of protein. Finally, relative transfection efficiencies were used to normalize
the transfer vector cytoplasmic RNA expression from the transfected cultures as well
as the number of hygromycin resistant CFU/ml.

2.3.4. Nucleocytoplasmic RNA Fractionation from the Transfected Cells:
For nucleocytoplasmic fractionation, 700µl of the total 1 ml transfected cell
culture was used by spinning in a microfuge for 2 minutes at 13000 rpm at 40 C. The
cell pellet was then resuspended in cold fractionation buffer [ diethylpyrocarbonate
(DEPC)-treated RLN buffer (50 mM Tris pH8.0, 140 mM NaCl, 1.5 mM MgCl2)]
supplemented with 0.5% NP40. After 5 minutes of incubation on ice to gently lyse
the cells without disrupting the nuclear membrane, lysates were spun down in a
microfuge at 300g for 2 minutes and 90% of the supernatant containing the
cytoplasmic fraction was carefully transferred to eppendorf tubes containing Trizol
(Invitrogen Life Technologies) for subsequent RNA isolation.
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2.3.5. Virus Isolation
The clarified supernatants containing virus particles from the transfected
cultures were subsequently passed through 0.2-m cellulose acetate syringe filters to
ensure no cellular components were present. The maximum equal volume remaining
in all the different supernatants were transferred to the bottom of ultra-clear
centrifuge tubes (Beckman) containing a cushion of 2 ml 20% sucrose cushion. The
tubes were topped up with fresh medium for balancing and ultracentrifuged in SW41
rotor at a speed of 26,000 rpm for 2 hours at 40 C. The resulting virus pellets were
resuspended in 126 l of TNE buffer (50 mM Tris-Cl, pH7.4, 100mM NaCl, and 1
mM EDTA, pH8.0) and lysed in 500 l Trizol LS reagent (Invitrogen Life
Technologies) containing 5 l of polyacryl (Molecular Research Center, OH) as a
carrier to isolate virion RNA.

2.4.

RNA Isolation:
The cytoplasmic fractions and viral particles resuspended in Trizol and Trizol

LS reagents, respectively, were used for RNA extraction. Towards this end, samples
in Trizol were incubated for 5 minutes at room temperature and then extracted with
120µl chloroform. Phase separation was achieved by centrifugation at maximum
speed in a microfuge (13000 rpm) for 15 min at 40 C. Next, the upper aqueous phase
containing the RNA was transferred to the new tubes containing 600µl isopropyl
alcohol and incubated at room temperature for 10 minutes. Samples were then
centrifuged at maximum speed in a microfuge (13000 rpm) for 10 min at 40 C. The
supernatant was decanted and resulting RNA pellets were washed with 1 ml of 70%
ethanol. The tubes were mixed gently to loosen the pellet and centrifuged in a
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microfuge at 10,000 rpm for 5 minutes at 40 C. After decanting the ethanol pellets
were air dried. Finally, the pellets were resuspended in 100µl RNase-free water,
vortexed and incubated at 550 C for 10 minutes to dissolve the pellets were stored at
-80 ºC.

2.5

Reverse Transcriptase PCR (RT-PCR)
Before embarking for RT-PCR it was imperative that we ensure that our

RNA preparations did not have any plasmid DNA that might have been carried over
from transfected cultures.

Towards this end, 25 µl viral RNA or 1-2 g of

cytoplasmic RNA fractions were DNase-treated using 2 units RQ1 RNase-Free
DNase (Promega, Madison, WI) at 370 C for 30 minutes in a mixture containing 10X
DNase Buffer and 20 units of Recombinant RNasin (Promega, Madison, WI).
Reactions were then the reaction was stopped by adding the stop solution containing
20mM EGTA (Promega, Madison, WI) at 1X concentration to the reaction mixture
and heat inactivating the samples at 650 C for 10 minutes in a shaking Thermomixer.
DNase-treated RNA samples were subjected to 30 cycle PCR to test for any residual
contaminating plasmid DNA, if any, using MPMV specific primer pair: OTR 1161
(S; 5’ GAT CAG AAC ACT GTC TTG TC 3’) and OTR 1163(AS; 5’ CTT TCT
TAT CTA TCA ATT CTT TAA 3’).
Once confirmed that RNA preparations were clear of any DNA
contamination, DNAse treated RNAs were reverse transcribed to make cDNA.
Briefly, DNased-RNA samples were incubated with 3µl of 25mM dNTPs and 300
ng of random hexamers (OTR 603; 5’ NNNNNN 3’) for 5 minutes at 700 C,
followed by quick cooling on ice for 5 minutes. Samples were then spun down and
the cDNA synthesis was initiated by the addition of a reaction mixture containing
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200 units of moloney murine leukemia virus (MoMuLV) reverse transcriptase
(Promega, Madison, WI) in the presence of 40 units of Recombinant RNasin
(Promega, Madison, WI) to inhibit RNAse activity for one hour at 370 C. cDNAs
prepared from the cytoplasmic RNAs were tested for the integrity of the RNA
fractionation process

by amplifying 1µl of cDNA to look for the absence of

unspliced β-actin mRNA which is exclusively found in the nucleus (Tan et al., 1995)
using OTR582 (S; 5’ CCAGTGGCTT CCCCAGTG 3’) and OTR581 (AS; 5’
GGCATGGGGGAGGGCATACC 3’).

For this purpose, a multiplex PCR was

performed using the OTRs 581/582 and the primers/competimers for 18S ribosomal
RNA (Ambion, TX) as a control for the presence of amplifiable cDNA during the
PCR. In order to further check that transfer vector RNAs were efficiently exported
out of the nucleus, 1 µl of the cytoplasmic cDNA samples were amplified using an
MPMV-specific transfer vector primer pair (OTRs 1161/1163) for 30 cycles.
Similarly, cDNA preparations from viral RNA samples were also amplified using
the same MPMV specific transfer vector primer pair (OTR 1161/1163) to
qualitatively check the transfer vector RNA packaging.

2.6.

Real time quantitative PCR (qPCR) for estimation of mutant

RNA packaging efficiency
The cytoplasmic and viral cDNA samples were used to quantify the relative
expression of the various transfer vector RNAs in the cytoplasm and their packaging
efficiency into the nascently-produced virions. Quantification was performed by
developing a Taqman quantitative gene expression real time PCR assay (Applied
Biosystem). This custom-made assay employed a FAM-labelled probe along with
primers within the U5/PBS region of MPMV, a region which was common to the
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wild type and all the mutant transfer vector RNAs and away from any site of
mutation. This resulted in restriction of where the assay could be designed which
specifically consisted of a sense primer (5' CTCCTCCAGGTTCCTACTGTTGA 3';
nt 702 to 724) an antisense primer (5' TCGTATCCAGCCCCACGTT 3'; nt 770 to
752), and a FAM-labeled probe (5' TCGGGACAGTTGGC 3'; nt 734 to 747). The
PCR efficiency of the MPMV assay was calculated using the online PCR Efficiency
Calculator (http://srvgen.upct.es/index.html) which gave a predicted value of 1.86.
This value fell slightly below the level suggested for the use of the ΔΔCT method (≥
1.9).

To ensure that we could use this method for the relative quantification

purposes, the assay was empirically tested against the standard curve method (see
Results for details) using test samples with varying amounts of MMTV RNA. This
comparative analysis validated the use of the ΔΔCT method for the quantification
purposes.
Thus, this method was used for all subsequent analyses and necessitated the
use of an endogenous control.

Towards this end, a pre-designed VIC-labelled

human ß-Actin assay (Applied Biosystems #4326315E) was used. Equal amounts of
cDNAs from the wild type and mutant samples were tested in triplicates for both the
MPMV and β-Actin assays. A 20 µl PCR mix was prepared per sample containing
2µl cDNA and 10 ul of the Taqman Universal Master Mix (Applied Biosystems
#4440045). The reaction was amplified for 50 cycles using the qPCR 7500 (Applied
Biosystems Inc. CA USA) and analyzed as per protocol. The RQ values thus
obtained for MPMV expression in both the cytoplasmic and viral samples were
normalized to the luciferase values obtained per µg protein to control for differences
in transfection efficiencies. Finally, to estimate the packaging efficiency, the results
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obtained for MPMV expression in the virions were divided by those for the
cytoplasmic expression and then reported relative to the wild type levels.

2.7.

MPMV RNA secondary structure analyses In Silico
The 5' end of the MPMV 5’ end genome (region between R and the first 120

nt of Gag) was folded using the RNA folding software “Mfold” (Mathews et al.,
1999; Zuker, 2003) to correlate the effects of the introduced mutations on MPMV
packaging signal RNA secondary structure.

2.8.

Statistical Analysis:
The statistical analysis was performed employing the standard paired 2-tailed

student t-test between the wild type and the mutant clones to establish statistical
significant differences. A P-value of 0.01 was considered to be significant.
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Chapter 3: Results
The predicted as well as SHAPE-validated secondary structures of MPMV
packaging signal RNA have shown two phylogenetically conserved LRIs (LRI-I and
LRI-II) involving U5 and Gag sequences. Additionally, the entire region seems to
be anchored by three stem-loops, namely SL3, Gag SL1, and Gag SL2 (Figure 1.13).
However, neither the two LRIs nor the three stem-loops have been tested empirically
for establishing their biological significance during MPMV RNA packaging and
propagation processes. Therefore, to provide functional evidence for the existence
of U5-Gag LRIs and the three stem loops, and validate their biological significance
to the MPMV life cycle, a series of mutations were introduced and their effects on
MPMV RNA packaging and propagation tested in a biological relevant transcomplementation assay.

3.1.

Experimental

approach

and

three

plasmid

trans-

complementation assay to determine MPMV RNA packaging and
propagation efficiencies
The sequences involved in formation of the U5-Gag LRIs fall in a region that
has been earlier reported to be important for both MPMV RNA packaging and
dimerization (Figure 1.12; Jaballah et al., 2010; Schmidt et al., 2003; Aktar et al.,
2013). Therefore, it becomes difficult to test the effects of the introduced mutations
in U5-Gag LRIs in the full-length genome context since it is very likely that
mutations introduced in this region might affect the flanking packaging
determinants. To overcome such a caveat, we took advantage of the three-plasmid
trans-complementation assay developed earlier in our laboratory for MPMV that
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provides the necessary biological components and the environment to generate virus
particles containing the packaged RNA, the replication of which is limited to a single
round because re-infection of the target cells cannot take place (Figure 2.3).

The

assay requires co-transfection of 293T producer cells with three different plasmids,
two of which produce viral structural and enzymatic proteins Gag/Pol and Env in
trans to produce viral particles, while the third plasmid (sub-genomic transfer
vector) produces the RNA which works as a substrate to be packaged into the
resulting virus particles. Such a scheme allowed us to introduce mutations in the
U5-Gag LRIs as well as in SL3, Gag SL1, Gag SL2 and study their effects on RNA
packaging without affecting the Gag/Pol ORFs since these proteins were provided in
trans from a separate expression plasmid. Briefly, a wild type (SJ2) or mutant
transfer vector, a Gag/Pol packaging construct (TR301), and an envelope expressing
plasmid (MD.G), along with a firefly luciferase expression plasmid (pGL3C) were
co-transfected into the producer 293T cells. The resulting virus particles were used
to test the effect of the mutations on MPMV RNA packaging by quantifying the
amount of packaged RNA, using real time PCR (qPCR). Virus particles were also
used to monitor the propagation of the packaged transfer vector RNA in the infected
HeLa T4 cells following their transduction with the marker hygromycin resistant
gene. The number of hygromycin resistant colonies should be directly proportional
to the packaged viral RNA content, providing an indirect estimate of RNA
packaging efficiency (Figure 2.3).
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3.2. Development of an MPMV custom-designed qPCR assay for
measuring the relative packaging efficiency of mutant viral RNAs
To determine the effect of the mutations on MPMV RNA packaging, a
quantitative qPCR assay needed to be developed that could be used to measure the
packaging efficiency of all mutant vector RNAs irrespective of the mutation they
displayed. This was achieved by designing a Taqman real time PCR assay that
employed a FAM-labelled probe along with primers that bound within the U5/PBS
region of MPMV (nt 702 to 770), a region that was common to the wild type as well
as all the mutant transfer vector RNAs and away from any of the mutations
introduced, ensuring 100% complementary binding efficiency of the primers and
probe to the target sites. The PCR efficiency of the MPMV assay was calculated
using the online PCR Efficiency Calculator (http://srvgen.upct.es/index.html)
(Mallons et al., 2011) which gave a predicted value of 1.86, a value that fell slightly
below the level suggested for the use of the ΔΔCT method (≥ 1.9). To ensure that
we could use this method for the relative quantification purposes, the assay was
empirically tested against the standard curve method using test samples with varying
amounts of MPMV RNA.
The ΔΔCT relative quantification method requires > 90% efficiency of
amplification of the custom assay since the values obtained from this data are
normalized to the amplification of an internal endogenous control (ß-actin in our
case) that has a guaranteed 100% efficiency of amplification. Therefore, the first
step was to determine the amplification efficiency of the custom assay empirically.
This was achieved by testing a series of 10-fold diluted MPMV plasmid starting
from 100 pg up to 0.01 pg (5 points). Similarly, a 10-fold serial dilution of a
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cytoplasmic cDNA sample expressing ß-actin was tested starting from 100 ng up to
0.01ng (5 points). The amplification efficiency curves obtained from the two assays
were compared. The value of the slope of log input amount verses ΔCT should be
approximately zero for the two assays to have similar amplification efficiencies.
However, we observed a value of 1.83, suggesting that the custom made assay was
on the borderline of accepted efficiency level. Therefore, we decided to empirically
test whether the assay was valid for use in packaging efficiency calculations.
This was achieved by testing the level of MPMV expression on a set of 12
unknown samples with variable MPMV expression in the cytoplasm and virions by
both the standard curve and ∆∆CT method. The standard curve method required
running a standard curve of MPMV SJ2 plasmid DNA dilutions as well as dilutions
of an actin expression plasmid alongside the unknown samples and estimating the
relative amounts of MPMV and actin in the unknown samples compared to the
values obtained from the two standard curves. The ∆∆CT method, on the other
hand, did not need the two standard curves for estimating relative expression in the
unknowns; instead, it used the endogenous β-actin expression to normalize for the
amount of cDNA used in estimating the expression of MPMV in each sample
relative to a calibrator sample that was “mock” cDNA in our case. Thus, the two
distinct methods were used to estimate MPMV expression in the 12 unknown
“cytoplasmic” and “viral” samples.
Figure 3.1 panels A and C show the results of MPMV expression in the
cytoplasm, while panels B and D show the relative packaging efficiency in the virus
particles, respectively, using the relative standard curve and ∆∆CT method. The
relative packaging efficiency was calculated by normalizing the RQ values obtained
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Figure 3.1. Validation of the custom-made MPMV real time PCR assay.

In

order to use the MPMV real time PCR assay to quantify the effect of the mutations
on gRNA packaging, the assay validity was tested using two methods: (A and B)
the relative standard curve method, and (C and D) the ∆∆CT method. The relative
standard curve method involved running a standard curve where a 10-fold serial
dilution of the MPMV wild type transfer vector plasmid, SJ2, was tested in
triplicates as the standard curve for MPMV, while a similar 10-fold serial dilution
was made of an SJ2-expressing cDNA as the standard curve for the endogenous βactin assay. A set of unknown samples from A to H expressing MPMV RNAs at
different levels in the cytoplasm (panels A and C) and packaged into virions
(panels B and D) were tested by both methods in addition to SJ2 cDNA as a
positive control and a mock sample serving as a negative control as well as the
calibrator in the ∆∆CT method. The ∆∆CT method was used to estimate MPMV
expression in the unknown samples relative to the endogenous β-actin expression.
The relative fluorescence values (RQ values) thus obtained in the unknown samples
were subsequently normalized to the transfection efficiency differences as measured
by the luciferase assay.

These values were used to calculate the packaging

efficiency of the unknown samples by dividing the normalized RQ values obtained
from the cytoplasmic expression of MPMV with that obtained for the MPMV
expression in the virions. Both methods gave a similar pattern of relative expression
in the unknown samples, revealing that the ∆∆ CT method could be used for
calculating the RNA packaging efficiency of the virions.

Finally, the results

obtained for MPMV expression in the virions were normalized to those for the
cytoplasmic expression and then reported relative to the wild type levels.

89

for MPMV expression in both the cytoplasmic and viral samples to the luciferase
values obtained per ug protein to control for differences in transfection efficiencies.
As can be seen, the relative pattern of expression estimated from the two very
different analyses yielded very similar results, thus validating the assay for use in the
estimation of mutant RNA packaging efficiency (Figure 3.1). Therefore, the ∆∆CT
method was used in all subsequent estimations of MPMV expression rather than the
standard curve method. This circumvented the need to generate a standard curve for
both MPMV and actin each time an assay was done, greatly facilitating the analysis
of RNA packaging efficiency.

3.3. Role of the wobble guanine-uracil (G-U) base-pairing in U5-Gag
complementary sequences of LRI-I and LRI-II during MPMV RNA
packaging and propagation
A distinguishing feature of the MPMV packaging signal RNA secondary
structure is the presence of two long range interactions, LRIs (LRI-I and LRI-II)
(Figure 3.2A). These LRIs are located within a region that has been shown to be
phylogenetically conserved in different MPMV strains and important for MPMV
RNA packaging and dimerization (Jaballah et al., 2010; Schmidt et al., 2003; Aktar
et al., 2013). We hypothesized that these LRIs could potentially play a role in
MPMV RNA packaging by maintaining the overall RNA secondary structure of the
whole 5’ UTR region that seems to be anchored by complementary and conserved
U5 and Gag sequences, (Figure 3.2A). A careful analysis of the sequences involved
in U5-Gag LRI-I revealed that out of the 13 complementary nucleotides, four basepaired nucleotides were present as non-Watson-Crick guanine-uracil (G-U) base-

Figure 3.2: Design and test of the deletion/substitution mutations introduced into the complementary U5-Gag LRI-I sequences.
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Figure 3.2. Design and test of the deletion/substitution mutations introduced
into the complementary U5-Gag LRI-I sequences. (A) Illustration of the SHAPEvalidated structure of the MPMV packaging signal RNA with long range interaction
regions I and II (LRI-I and LRI-II) highlighted in red boxes. The predicted
complementary 8 nucleotide U5-Gag sequence of LRI-II is shown in blue box with
hatched lines. (B) Table outlining the deletion/substitution mutations introduced into
the U5-Gag sequences of LRI-I.

Sequences of the mutations introduced are

represented in lower case and in red color. The mutant transfer vectors RK1 and
RK2 contain LRI-stabilizing substitution mutations where the uridines were
substituted with cytosines, forming wobble base pairs in LRI-I only in RK1 or LRI-I
and LRI-II in RK2, respectively. RK3, RK4, and RK5 are deletion mutants in LRI-I
as described in the table. RK6 contains a substitution of the X-I sequence with
heterologous sequence so that the complementarity between U5 and Gag (X-I and YI) is lost. In RK7, an artificial LRI-I is re-established by substituting the Gag (Y-I)
sequence with a complementary heterologous sequence to the one introduced in
RK6. Asterisk (*) denotes that only part of the U5 sequence for both LRIs is shown
due to space limitations. (C) Representative gel images of the controls needed for
validating different aspects of the three plasmid trans complementation assay. (I)
PCR amplification of DNase-treated RNA from the cytoplasmic (upper panel) and
viral (lower panel) RNA preparations with MPMV-specific vector primers (II)
multiplex amplification of unspliced β-actin mRNA and 18S rRNA and (III) PCR
amplification of spliced β-actin mRNA to check for the nucleocytoplasmic
fractionation technique (IV) PCR amplification of transfer vector cytoplasmic
cDNAs using MPMV vector-specific primers.
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pairs (Figure 3.2A). Since we have proposed that the complementary nature of the
LRI sequences play a role in anchoring the RNA structure; therefore, we reasoned
that further strengthening the base-pairing between the U5 and Gag sequences of the
LRI-I should potentially make the structure more stable, resulting in enhanced RNA
packaging. With this rationale in mind, we created a mutant transfer vector (RK1) in
which the four uridine (U) residues in the U5 sequence (X-I) of the LRI-I involved
in the low affinity G-U wobble base-pairing were substituted by cytosines (C) to
form strong and stable Watson G-C base pairings (Figure 3.2A and 3.2B). Similarly,
in the case of LRI-II where two out of the eight complementary nucleotides have the
G-U (non-Watson-Crick, wobble base-pairing), we substituted two uracil (U)
residues in the U5 sequence (X-II) of the LRI-II with cytosines (C), creating another
mutant transfer vector (RK2). For creating RK2, we used the mutant clone RK1
DNA as a template to substitute the additional two uridine residues, and in doing so
converted a total of six G-U (non-Watson-Crick, wobble base-pairs) into Watson
stable G-C base pairs (Figure 3.2A and 3.2B).
To test the effects of the introduced mutations on RNA packaging, the wild
type (SJ2) and mutant transfer vectors (RK1 and RK2) along with the MPMV
packaging construct (TR301), the envelope expression plasmid (MD.G), in the
presence of firefly luciferase expressing plasmid, pGL3, were co-transfected into
293T producer cells. Following the experimental protocol described in Materials
and Methods, the viral supernatants from transfected cultures were harvested and
used to isolate viral RNA to determine RNA packaging and to infect HeLa T4 cells
in order to monitor the packaged vector RNA propagation.
Following transfection and prior to successful RNA packaging, it is
imperative that mutant transfer vectors RNAs are stably expressed and efficiently
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exported to the cytoplasm. Therefore, to ensure these crucial steps in viral life cycle,
the transfected cells were fractionated into cytoplasmic and nuclear fractions. Next,
RNAs were prepared from both the cytoplasmic fractions and the pelleted viral
particles and analyzed by RT-PCR for the integrity of fractionation and MPMV
expression. To exclude the possibility of any contaminating plasmid DNA that may
have carried over from the transfected cultures, RNA preparations were treated with
RNase-free DNase and PCR amplified for 30 cycles using MPMV vector-specific
primers. A lack of any demonstrable amplification signal in DNase treated RNA
samples suggested that any plasmid DNA contamination, in these RNA preparations
was below the detection level (Figure 3.2C.I; upper panel cytoplasmic RNA; lower
panel viral RNA). After having ensured this, cDNAs from the DNase-treated RNAs
were prepared and integrity of the nucleo-cytoplasmic fractionation technique was
tested by ensuring that no RNA physically leaked from the nucleus to the cytoplasm
due to rupturing of the nuclear membrane during the fractionation process. This was
achieved by testing for the presence of unspliced β-actin mRNA in the cytoplasmic
fractions, an mRNA that should remain exclusively nuclear, while the spliced β-actin
mRNA should be observed in both the fractions.
Test of the cytoplasmic cDNAs revealed that the unspliced β-actin mRNA
could not be detected in any of the samples prepared even though it could be
detected in the nuclear fraction, which also served as a positive control (Figure
3.2C.II). On the other hand, the spliced β-actin mRNA was observed in all the
cytoplasmic fractions (Figure 3.2C.III). The absence of any amplifiable signal for
unspliced β-actin mRNA which is exclusively found in the nucleus suggested that
the nuclear membrane integrity was not compromised during fractionation and our
RNA preparations were bona fide cytoplasmic (Figure 3.2C.II).

Since our
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interpretations were based on the inability of unspliced β-actin mRNA to be
amplified from the cytoplasmic RNA fractions, it was important to ascertain that
each sample during PCR contained amplifiable cDNAs. To establish this, unspliced
β-actin amplifications were performed as a multiplex PCR in the presence of
primers/competimer for 18S ribosomal RNAs as an internal control. Successful
amplification of 18S ribosomal RNAs across all the samples validated the presence
of amplifiable cDNAs (Figure 3.2C.II). Finally, cDNAs prepared from cytoplasmic
RNA fractions were amplified using MPMV transfer vector-specific primers and the
amplification signal across all the samples ensured that the transfer vector RNAs
were efficiently and stably expressed and properly transported from the nucleus to
the cytoplasm (Figure 3.2C.IV).
Having taken into consideration all the necessary controls, we next analyzed
the packaging efficiencies of the transfer vector RNAs transcribed from RK1 and
RK2 (containing substitutions in G-U base-pairing in the U5-Gag complementary
sequences of LRI-I and LRI-II) in virus particles relative to the wild type (SJ2)
transfer vector RNA. Towards this end, the MPMV custom-designed qPCR real
time assay was used in combination with a commercially available β-actin Taqman
assay as an endogenous control on both the cytoplasmic and virion RNA samples in
triplicates as described earlier. The viral RNA packaging results obtained were
further normalized to their cytoplasmic expression (Figure 3.3C.I) and the
transfection efficiency (data not shown) to determine the packaging efficiency of
RK1 and RK2. Next, the ratio of packaged mutant RNA was calculated relative to
the wild type RNA to determine the relative packaging efficiency (RPE) of each
mutant transfer vector RNA (Figure 3.3C.II). Such an analysis revealed that the
RNA packaging efficiency of the LRI-1-stabilizing mutants (RK1 and RK2) was
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Figure 3.3. Effect of the deletion/substitution mutations introduced into U5-Gag LRI-I
on MPMV gRNA packaging and propagation. (A) Illustration of the SHAPE-validated
structure of the MPMV packaging signal RNA with long range interaction regions I and II
(LRI-I and LRI-II) highlighted in red boxes. The predicted complementary 8 nucleotide U5Gag sequence of LRI-II is shown in blue box with hatched lines. (B) Table outlining the
deletion/substitution mutations introduced into the U5-Gag sequences of LRI-I. Sequences
of the mutations introduced are represented in lower case and in red color. The mutant
transfer vectors RK1 and RK2 contain LRI stabilizing substitution mutations where the
uridines were substituted with cytosines, forming wobble base pairs in LRI-I only in RK1 or
LRI-I and LRI-II in RK2, respectively. RK3, RK4, and RK5 are deletion mutants in LRI-I
as described in the table. RK6 contains a substitution of the X-I sequence with heterologous
sequence so that the complementarity between U5 and Gag (X-I and Y-I) is lost. In RK7, an
artificial LRI-I is re-established by substituting the Gag (Y-I) sequence with a
complementary heterologous sequence to the one introduced in RK6. Asterisk (*) denotes
that only part of the U5 sequence for both LRIs is shown due to space limitations. (C)
Relative cytoplasmic expression and packaging efficiencies of MMTV transfer vector RNAs
as measure by the ∆∆CT method, and propagation efficiencies of LRI-I mutant transfer
vectors. Panel (I) Cytoplasmic transfer vector RNA expression in 293T cells relative to the
wild type (SJ2 vector) after normalization with the β-actin endogenous control and luciferase
expression. Panel (II) mutant transfer vector RNA packaging efficiencies relative to the
wild type (SJ2) after normalization with β-actin and luciferase expression. Panel (III)
Relative hygromycin resistant colony-forming units (CFU)/ml for mutant transfer vectors
reflecting the relative propagation efficiencies compared to the wild type SJ2 vector. The
data represented in histograms correspond to the mean of the samples when tested in
triplicates (± SD) following transfection and infection experiments.
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affected when compared to the wild type transfer vector SJ2 (2.5- and 2.0-fold
reduction in RPEs for RK1 and RK2, respectively; P<0.01; Figure 3.3C.II), in sharp
contrast to our expectations. In agreement with the RNA packaging data, it was
observed that these mutants were also proportionally defective for RNA propagation
when compared to the wild type, SJ2 (Figure 3.3C.III). The RNA propagation
defects in these mutants were observed by counting the hygromycin resistant
colonies (colony forming unit/ml; CFU/ml) that appeared in the transduced HeLa T4
cells following infection with the virus particles containing hygromycin resistance
gene on packaged transfer vector RNA.

Such effects on RNA packaging and

propagation were observed despite the fact that the transfection efficiencies for these
mutants (RK and RK2) and wild type (SJ2) in multiple experiments were within 2folds of each other (data not shown) and real time qPCR analysis of mutant transfer
vector RNA showed steady-state levels of expression in the cytoplasm relative to the
wild type, SJ2 (Figure 3.3C.I). Contrary to our predictions, this data suggest that
further strengthening the base-pairing of U5-Gag LRIs adversely affects both RNA
packaging and propagation.

3.4. Role of the U5-Gag complementary sequences in maintaining
LRI-I structure during MPMV RNA packaging and propagation
To investigate the role of the complementary sequences involved in the U5Gag LRI-I, a series of mutations were introduced in a fashion that either disrupted
the complementarity between U5 and Gag sequences or completely deleted the
complementary sequences (Figure 3.2A and 3.2B). In mutant transfer vectors RK3
and RK4, the complementarity between the U5 and Gag sequences was perturbed
due to the deletion of U5 (X-I) and Gag (Y-I)

complementary sequences,
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respectively, while RK5 contained a double deletion in which both the U5 (X-I) and
its complementary Gag (Y-I) sequences involved in forming the LRI-I were deleted
simultaneously (Figure 3.2A and 3.2B).

Such drastic double mutations were

introduced to determine whether MPMV could package its RNA in the absence of
LRI-I while maintaining only LRI-II. These mutant transfer vectors (RK3-RK5)
were tested in our in vivo packaging and propagation assay to assess the effects of
the introduced mutations on MPMV RNA packaging and propagation.
After having confirmed the absence of any contaminating plasmid DNA in
our cytoplasmic and viral RNA preparations (Figure 3.2C.I), we ensured that nuclear
membrane integrity was maintained during cytoplasmic RNA fractionation, that
cDNA preparations were amplifiable (Figure 3.2C.II and III), and the transfer vector
RNAs were stably expressed and efficiently exported to the cytoplasm (Figure
3.2C.II and IV). Next, results obtained from qPCR real time assay were calculated
to determine the packaging efficiencies of RK3-RK5 relative to the wild type (SJ2)
levels following normalization to the cytoplasmic transfer vector RNA expression
(Figure 3.3C.I) as well as to the transfection efficiency (data not shown). Results
obtained following these analyses demonstrated that deletion of either one (U5-X-I
in RK3 or Gag-Y-I in RK4) or both complementary sequences (RK5) involved in
LRI-I almost abolished RNA packaging (>10-folds compared to the wild type;
Figure 3.3C.II). Consistent with the RPEs of RK3-RK5, the propagation efficiencies
of these transfer vector RNAs were also proportionally reduced (Figure 3.3C.III).
Data obtained from these biological tests suggested that maintenance of LRI-I
involving complementary U5 and Gag sequences is crucial for MPMV RNA
packaging. These results also suggest that the mere presence of only LRI-II is not
sufficient to encapsidate MPMV RNA in the budding virus particles.
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In light of the above observations, it was necessary to establish whether it is
the primary sequence of the complementary U5 and Gag nucleotides important for
RNA

packaging or

the

non-viral

heterologous

nucleotides

keeping

the

complementarity between U5 and Gag sequences would be sufficient to maintain the
LRI-I and therefore RNA packaging. Thus, two mutants were generated to address
these possibilities.

In the RK6 mutant clone, one side of the complementary

sequence (U5; X-I) was substituted with heterologous sequences of equal length (5’
AUCUCUUAUAUAU 3’) so that its complementarity with the sequence on the
other side (Gag; Y-I) was lost (Figure 3.2A and 3.2B). Specifically, substitution of
U5 with such a heterologous sequence resulted in loss of base-pairing for four
nucleotides, four nucleotides assumed non-Watson-Crick, wobble (G-U) basepairing, and five nucleotides maintained their wild type base-pairing with the Gag
(Y-I) sequence. We expected this mutant to display severely compromised RNA
packaging and propagation if the LRI was required for stabilizing the overall higher
order structure and consequently the function of packaging signal RNA sequences.
Next, RK7 was constructed that contained a compensatory mutation in which the
Gag

(Y-I)

sequence

in

RK6

was

substituted

with

the

sequence

5’

AUAUAUAAGAGAU 3’ complementary to the heterologous sequence substituted
in RK6, thus restoring the artificial/heterologous LRI-I in place of the original U5Gag LRI (Figure 3.2A and 3.2B). Consistent with the deletion mutants RK3-RK5,
disruption of the LRI-I complementarity in RK6 (due to the substitution of U5 (X-1)
sequence with a heterologous one) almost abolished RNA packaging (> 20 fold
reduction; P<0.01 compared to the wild type SJ2; Figure 3.3C.II). Consistent with
our assumption, restoration of LRI-I with heterologous sequences in RK7 not only
restored RNA packaging, but it was observed to be more than the wild type levels
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(Figure 3.3C.II). The low level of RNA packaging in the case of RK6 corroborated
well with the reduced RNA propagation observed for this mutant (25 fold reduction;
P<0.01 compare to the wild type SJ2; compare Figure 3.3C.II with Figure 3.3C.III).
Similarly, restoration of RNA packaging with the re-establishment of LRI-I with
heterologous sequences in the case of RK7 also restored RNA propagation of this
mutant to wild type levels (compare Figure 3.3C.II with Figure 3.3C.III). These
results biologically validate the existence of LRI-I and further suggest its role at the
structural level rather than at the primary sequence level since re-establishment of
artificial/heterologous LRI-I at its native location restored RNA packaging and
propagation to wild type levels.

3.5. Role of the U5-Gag complementary sequences in maintaining
LRI-II during MPMV RNA packaging and propagation
A similar mutational approach was employed towards investigating the role
of U5-Gag complementary sequences involved in forming LRI-II. Thus, a series of
substitution, deletion, and compensatory mutations were first introduced in the eight
nucleotide U5 and Gag region involved in forming LRI-II and tested for their effect
on MPMV RNA packaging and propagation. In the mutant transfer vector RK8, all
eight nucleotides within the U5 (X-II) that were predicted to be paired with Gag (YII) sequence were substituted with heterologous eight nucleotides (5’ AGAUAGAG
3’) to lose the U5-Gag complementarity responsible for maintaining LRI-II (Figure
3.4A and 3.4B). In the substitution mutant RK9, the U5 (X-II) sequences were
replaced by its complementary sequences in Gag (Y-II), thus duplicating the
sequence of Gag (Y-II) on both ends of LRI-II, resulting in the disruption of U5-Gag
complementarity in six out of the eight nucleotides (Figure 3.4A and 3.4B). Mutant
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Figure 3.4. Design and test of the deletion/substitution mutations introduced into the
U5-Gag LRI-II sequences.

(A) Illustration of the SHAPE-validated structure of the

MPMV packaging signal RNA with long range interaction regions I and II (LRI-I and LRIII) highlighted in red boxes. The predicted complementary 8 nucleotide U5-Gag sequence of
LRI-II is shown in blue box with hatched lines. (B) Table outlining the deletion/substitution
mutations introduced into the U5-Gag sequences of LRI-II. Sequences of the mutations
introduced are represented in lower case and in red color. Two sets of mutants are outlined
in the table. The first set of mutations were introduced into the Mfold- predicted 8 nt LRI-II
structure, while the second set describes mutations introduced into the SHAPE-validated
LRI-II structure. The mutant transfer vectors RK8 and RK9 contain substitutions mutations
in the X-II sequence, while RK10 contains substitutions mutations in the Y-II sequence.
These substitutions caused a loss of complementarity between U5 and Gag (X-II and Y-II).
In RK11, an artificial LRI-I was re-established by flipping the original LRI-II strand
sequences while still maintaining the wild type complementarity. In RK12, the SHAPEvalidated X-II sequence was deleted completely. In RK13, the deleted sequence in RK12
was substituted with heterologous sequences which resulted in the loss of complementarity.
In RK14, the complementarity of LRI-II was restored by substituting the Y-II sequence with
heterologous sequences complementary to the X-II sequence of RK13. Asterisk (*) denotes
the 8 nucleotide U5 sequence of the predicted LRI-II. Asterisks (**) denote the 9 nucleotide
U5 sequence of the SHAPE validated LRI-II. (C) Representative gel images of the controls
needed for validating different aspects of the three plasmid trans complementation assay.
(I) PCR amplification of DNase-treated RNA from the cytoplasmic (upper panel) and viral
(lower panel) RNA preparations with MPMV-specific vector primers

(II) Multiplex

amplification of unspliced β-actin mRNA and 18S rRNA and (III) PCR amplification of
spliced β-actin mRNA to check for the nucleocytoplasmic fractionation technique (IV) PCR
amplification of transfer vector cytoplasmic cDNAs using MPMV vector-specific primers.
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transfer vector RK10 was designed in a fashion that the U5 (X-II) sequence was
duplicated in place of Gag (Y-II) sequence while maintaining the 5’ to 3’ polarity.
Such a strategy resulted in creating the U5 (X-II) sequence (5’ CUUGUUCC 3’) on
both ends of LRI-II (X-II and Y-II) in the same orientation. Thus, none of the eight
nucleotides maintained any complementarity with the complementary strand (Figure
3.4A and 3.4B). These substitution mutants (RK8-RK10) were tested in the in vivo
packaging assay, and the RPEs of these mutant transfer vectors were calculated after
taking into consideration all the necessary controls (Figure 3.4C.I-IV). Consistent
with our earlier observations as in the case of LRI-I mutants, RNA packaging of
these mutants, designed to disrupt the complementarity of U5 and Gag sequences of
LRI-II, was observed to be nearly ablated (Figure 3.5C.II). In good concordance
with the RNA packaging data, the RNA propagation of these mutant transfer vectors
was found to be severely compromised (Figure 3.5C.III).
In order to determine whether the primary sequence of the eight nucleotides
in U5 and Gag was essential in its native context in maintaining the predicted LRI-II
for RNA packaging, or any heterologous sequence maintaining the complementarity
at this location would be sufficient to augment RNA packaging, we created a double
complementary mutant, RK11 (Figure 3.4A and 3.4B). RK11 was created from the
RK9 mutant clone which already contained the substitution of U5 (X-II) sequence
with its complementary sequence in Gag (Y-II). RK9 was used as a template to
substitute the original Gag (Y-II) sequence with the U5 (X-II) sequence.

The

resulting double mutant (RK11) restored the complementarity between the two LRIII strands (X-II and Y-II) with a 180 degrees flipped orientation, re-establishing an
artificial LRI-II structure (Figure 3.4A and 3.4B), similar to RK7 in LRI-1.
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Figure 3.5. Effect of the deletion/substitution mutations introduced into U5-Gag
LRI-II in MPMV gRNA packaging and propagation. (A) Illustration of the
SHAPE-validated structure of the MPMV packaging signal RNA with long range
interaction regions I and II (LRI-I and LRI-II) highlighted in red boxes. The
predicted complementary 8 nucleotide U5-Gag sequence of LRI-II is shown in blue
box with hatched lines. (B) Table outlining the deletion/substitution mutations
introduced into the U5-Gag sequences of LRI-II.

Asterisk (*) denotes the 8

nucleotide U5 sequence of the predicted LRI-II.

Asterisks (**) denote the 9

nucleotide U5 sequence of the SHAPE validated LRI-II. (C) Relative cytoplasmic
expression and packaging efficiencies of MMTV transfer vector RNAs as measure
by the ∆∆CT method, and propagation efficiencies of LRI-II mutant transfer vectors.
Panel (I) Cytoplasmic transfer vector RNA expression in 293T cells relative to the
wild type (SJ2 vector) after normalization with the β-actin endogenous control and
luciferase expression.

The error bars represent the standard deviation (SD) of

triplicates of each clone.

Panel (II) mutant transfer vector RNA packaging

efficiencies relative to the wild type (SJ2) after normalization with β-actin and
luciferase expression. Panel (III) Relative hygromycin resistant colony-forming
units (CFU)/ml for mutant transfer vectors reflecting the relative propagation
efficiencies compared to the wild type SJ2 vector.

The data represented in

histograms correspond to the mean of the samples when tested in triplicates (± SD)
following transfection and infection experiments.
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Test of RK11 in the in vivo packaging and propagation assay revealed that it could
not restore RNA packaging and propagation of the mutant vector RNA (Figure
3.5C.II and III), an observation in sharp contrast to that in the case of LRI-I mutant
RK7, a double compensatory mutant designed to re-establish artificial/heterologous
LRI-I; Figure 3.3C.II and III). These results were rather unexpected, especially
given the fact that RK11 retains the primary viral sequences involved in forming
LRI-II, however, in an opposite orientation, thus re-establishing an artificial LRI-II.
These data therefore suggest that the predicted primary eight nucleotide
complimentary sequence of U5 (X-II) and Gag (Y-II) LRI-II in its native context is
vital for RNA packaging.
It is worth pointing out that the U5 and Gag sequences involved in forming
LRI-II differed somewhat between the predicted and SHAPE-validated secondary
structure of MPMV packaging signal RNA (Aktar et al., 2013). Specifically, a
uridine residue at position 62 (U62) maintains the G-U wobble base pairing in the
predicted structure, whereas in the SHAPE-validated structure, it did not assume the
G-U wobble base pairing since it was highly reactive to SHAPE reagents and
consequently formed a bulge in the U5 sequence (X-II) of LRI-II (Figure 3.4A;
Jaballah et al., 2010; Aktar et al., 2013). In addition, an extra cytosine at position 65
(C65) that was not originally predicted to be part of the U5 (X-II) complementary
sequences was included in the SHAPE-validated LRI-II structure and base-paired
with a complementary guanine (G) in the complementary Gag (Y-II) sequence.
Such a single nucleotide shift made the U5 (X-II) sequences involved in forming
LRI-II to be of nine nucleotides instead of eight nucleotides as initially predicted
(Jaballah et al., 2010; Aktar et al., 2013; Figure.3.4A). To investigate the role of U5
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and Gag sequences of LRI-II in MPMV RNA packaging, we initially introduced
mutations in the predicted structure of LRI-II involving complementary eight
nucleotides as described above. However, since the SHAPE-validated structure was
only recently published, we introduced another set of mutations in the SHAPEvalidated nine nucleotides of U5 (X-II) sequences of LRI-II (Figure.3.4A).
Therefore, to further confirm results obtained with the predicted eight
nucleotide LRI-II, we created a few more mutants in the nine nucleotide SHAPEvalidated LRI-II structure that contained one unpaired U in the U5 (X-II)
complementary to eight nucleotides in the Gag (Y-II) sequences (Figure.3.4A). In
an attempt to disrupt the complementary U5 (X-II) and Gag (Y-II) sequences, all the
nine nucleotides of U5 (X-II) sequence were deleted in RK12 (Figure 3.4A and
3.4B). Consistent with the mutational analysis with the predicted eight nucleotide
clones RK8 and RK9, test of RK12 (designed to disrupt the SHAPE-validated LRI-II
complementarity) revealed that both RNA packaging and propagation were almost
abrogated when compared to the wild type (SJ2; Figure 3.5C.II and III), further
confirming the importance of LRI-II to the packaging potential of MPMV.
Finally, to examine the importance of complementarity between the 9
nucleotides of U5 and Gag sequences involved in establishing the SHAPE-validated
LRI-II at the primary sequence level or at the structural level, two additional mutant
clones, RK13 and RK14, were created. RK13 is a substitution mutant in which the
U5 (X-II) sequence was substituted with heterologous sequences of an equal length
(5’ AGGAGGAGG 3’), resulting in the loss of complementarity between U5 and
Gag sequences of LRI-II (Figure 3.4A and 3.4B). Next, in an attempt to create an
artificial LRI-II with non-viral heterologous sequences, RK14 was created from
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RK13 in which complementarity was restored by substituting the Gag (Y-II)
sequence with the heterologous sequence, 5’ CCUCCUCCU 3’ (Figure 3.4A and
3.4B). As expected, RNA packaging and propagation of RK13 (designed to disrupt
the complementarity of the SHAPE-validated LRI-II) was essentially abrogated
(Figure 3.5C.II and III).

Not quite surprisingly, but consistent with RK11

(compensatory mutant designed to re-establish artificial LRI-II based on the
predicted structure), RK14 was unable to restore the packaging and propagation of
the mutant vector RNA and was observed to be severely impaired in its ability to
package and propagate its RNA (Figure 3.5C.II and III).

Together, these data

unambiguously suggest that it is the primary sequence of LRI-II that is important for
efficient MPMV RNA packaging and propagation. These results also show that the
primary sequence of LRI-II is critical in its native structural context only to augment
MPMV RNA packaging since recreation of the artificial LRI-II using primary viral
sequences in RK11 (maintaining complementarity, but in a flipped orientation)
failed to restore packaging or propagation to wild-type levels.

3.6. Role of sequences involved in forming stem loops at the 3’ end of
the SHAPE-validated structure during MPMV RNA packaging and
propagation
While the secondary structure of the 5’ UTR sequences that have been shown
to be important for MPMV RNA packaging appear to be anchored by
complementary U5 and Gag sequences forming LRI-I and LRI-II (Figure 3.6A)
sequences from the distal parts of the 5’ UTR and Gag (but excluding the Gag
sequences involved in forming U5-Gag LRIs) forming three stem loops (SL3, Gag
SL1, and Gag SL2) seem to provide stability to the overall RNA secondary structure
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Figure 3.6. Design and test of the systematic deletion mutations introduced in
sequences at the 3’ end of the SHAPE-validated structure forming SL3, Gag
SL1 and Gag SL2. (A) Illustration of the SHAPE-validated structure of MPMV
packaging signal RNA with SL3, Gag SL1 and Gag SL2 highlighted in red boxes.
(B) Table outlining the deletion mutations introduced in SL3 and Gag sequences. In
RK15, 16 and 17, single deletion of either SL3 sequence, Gag SL1 or Gag SL2 was
deleted respectively. Mutants RK17 and RK18 contain double deletion of SL3 along
with either Gag SL1 or Gag SL2, respectively. Mutant RK20 contains a triple
deletion of SL3, Gag SL1 and Gag SL2 (C) Representative gel images of the
controls needed for validating different aspects of the three plasmid trans
complementation assay. (I) PCR amplification of DNase-treated RNA from the
cytoplasmic (upper panel) and viral (lower panel) RNA preparations with MPMVspecific vector primers (II) Multiplex amplification of unspliced β-actin mRNA and
18S rRNA and (III) PCR amplification of spliced β-actin mRNA to check for the
nucleocytoplasmic fractionation technique (IV) PCR amplification of transfer vector
cytoplasmic cDNAs using MPMV vector-specific primers.
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of the 5’ of MPMV genome. In order to test this, a systematic deletion analysis of
the sequences involved in forming SL3, Gag SL1, and Gag SL2 was performed
(Figure 3.6A). The first mutant, RK15, contained a 33 nucleotide deletion (from the
distal part of the 5’ UTR) removing most of the sequences forming SL3 (Figure
3.6A boxed region and 3.6B). Next, a 30 nucleotide deletion was introduced in
RK16 to remove Gag SL2 (Figure 3.6A boxed region and 3.6B). Finally, a 39
nucleotide deletion was introduced in RK17 (boxed region in Figure 3.6A and 3.6B)
to remove Gag SL1. RNA packaging efficiencies for mutant clones RK15-RK17
were quantified after having taken into consideration all the necessary controls
(Figure 3.6C.I-IV). These results revealed that individual deletion of SL3, Gag SL1,
and Gag SL2 only marginally affected RNA packaging when compared to the wild
type (≤ 1-fold or 0.5, 0.7, and 0.6 relative to the wild type; Figure 3.7C.II). This
slight reduction in RNA packaging was in agreement with the RNA propagation data
which also exhibited minor reductions in hygromycin-resistant colonies obtained
compared to the wild type (Figure 3.7C.III). These results suggested that sequences
involved in forming SL3, Gag SL1, and Gag SL2 do not play crucial role at
individual levels during MPMV RNA packaging and propagation.
Redundancy is a common characteristic of retroviruses and it is possible that
when deleting only one of the three stem loops, the remaining stem loops
compensate for the loss of the deleted one for maintaining and stabilizing the major
structural motifs of the 5’ UTR important for MPMV RNA packaging and
propagation. To test this possibility, we created deletion mutant clones in which
sequences involved in forming SL3, Gag SL1, and Gag SL2 were deleted
simultaneously in multiple combinations.

In mutant clone RK18, the same

sequences that were deleted individually in RK15 (33 nt of SL3) and RK16 (39 nt of
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Figure 3.7: Effect of deletion mutations introduced into sequences at the 3’ end of the SHAPE-validated structure forming SL3, Gag
SL1 and Gag SL2 on RNA packaging and propagation.
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Figure 3.7. Effect of deletion mutations introduced into sequences at the 3’ end
of the SHAPE-validated structure forming SL3, Gag SL1 and Gag SL2 on RNA
packaging and propagation. (A) Illustration of the SHAPE-validated structure of
MPMV packaging signal RNA with SL3, Gag SL1 and Gag SL2 highlighted in red
boxes. (B) Table outlining the deletion mutations introduced in SL3 and Gag
sequences. In RK15, 16 and 17, single deletion of either SL3 sequence, Gag SL1 or
Gag SL2 was deleted respectively.

Mutants RK17 and RK18 contain double

deletion of SL3 along with either Gag SL1 or Gag SL2, respectively. Mutant RK20
contains a triple deletion of SL3, Gag SL1 and Gag SL2. (C) Relative cytoplasmic
expression and packaging efficiencies of MMTV transfer vector RNAs as measure
by the ∆∆CT method, and propagation efficiencies of stem-loop mutant transfer
vectors.

Panel (I) Cytoplasmic transfer vector RNA expression in 293T cells

relative to the wild type (SJ2 vector) after normalization with the β-actin endogenous
control and luciferase expression. The error bars represent the standard deviation
(SD) of triplicates of each clone. Panel (II) mutant transfer vector RNA packaging
efficiencies relative to the wild type (SJ2) after normalization with β-actin and
luciferase expression. Panel (III) Relative hygromycin resistant colony-forming
units (CFU)/ml for mutant transfer vectors reflecting the relative propagation
efficiencies compared to the wild type SJ2 vector.

The data represented in

histograms correspond to the mean of the samples when tested in triplicates (± SD)
following transfection and infection experiments.
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Gag SL1) were deleted simultaneously, creating a mutant clone with a 72 nucleotide
discontinuous deletion removing most of SL3 and all of Gag SL2 (Figure 3.6A and
3.6B). Employing a similar strategy, another double deletion mutant, RK19, was
created in which sequences involved in forming SL3 and Gag SL2 were
simultaneously deleted (a 63 nt discontinuous deletion; Figure 3.6A and 3.6B).
Finally, in a more drastic deletion, sequences involved in forming SL3, Gag SL1,
and Gag SL2 were simultaneously deleted (a 102 nt discontinuous deletion) to create
RK20 (Figure 3.6A and 3.6B).
There is a possibility such drastic deletion mutations (RK18-RK20) may
inadvertently affect transfer vector RNA expression and stability. Therefore, before
determining the effects of these mutations on RNA packaging, the cytoplasmic RNA
expression of these mutant clones were analyzed to look for their stable expression.
Results presented in Figure 3.6C.I-IV demonstrate that these transfer vector RNAs
were efficiently and stably expressed and exported to the cytoplasm. Next, the
packaging efficiency of the mutant clones relative to the wild type was determined
(Figure 3.7C.II) and was found to be significantly impaired (2.5-10 fold less
compared to the wild type). The most drastic impairment in RNA packaging was
observed in the triple deletion mutant RK20 which could be attributed to the rather
large (102 nt) deletion (~10-fold reduction; P<0.01; Figure 3.7C.II).

RNA

propagation in these mutant clones was observed to be proportionally reduced
(Figure 3.7C.III). Together, these results suggest that the three stem loops tested
above are important for stabilizing the structure of this region in a redundant
manner; removal of one of these stem loop results in compensation by the others in
stabilizing the structure. Compared to these mutants (RK18-RK20), many of the
LRI-I and II mutants involving only few nucleotides mutations resulted in drastic
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effects on the packaging and propagation potential of mutant vector RNAs. These
results revealed that U5-Gag LRIs have a more important architectural role in
stabilizing the structure of the 5’ UTR sequences (that have been shown to be
important for RNA packaging and dimerization), while the lower three stem loops
(SL3, Gag SL1, and Gag SL2) may have a more secondary role in stabilizing the
entire region.

3.7.

Structural Analyses of the mutants involving sequences

forming the LRIs and stem loops (SL3, Gag SL1, and Gag SL2) at
the 3’ end of the SHAPE-validated structure
To better understand the results of the mutations introduced into LRI-I, LRIII, SL3, and Gag SLs, a structural prediction analysis of these mutants was
performed to correlate the biological effect of the introduced mutations with their
predicted folded secondary structures.

3.7.1. Structure-function relationship of the sequences involved in U5-Gag
LRI-I
The secondary structure of the mutant transfer vector RNAs was predicted
using Mfold software (Mathews et al., 2003; Zuker, 1999). This algorithm predicts
the most stable secondary structure that the RNA can fold by calculating the
minimum free energy of each structure. The more negative the free energy, the more
stable the structure.

These mutants' RNA secondary structure predictions were

compared to the wild type structure of the same region in an attempt to establish a
structure-function correlation between the biological effect of the introduced
mutations in the sequences involved in the formation of U5-Gag LRI-I and their

-124.7

∆G (kcal/mol)

-134.9

0.36

1.00

RPE

X-I Y-I

Y-II

5’ acuccccgugucu 3’
3’ UGAGGGGCACAGA 5’

Gag
SL1

X-II

5’ AUUUCUUGUGUCU 3’
3’ UGAGGGGCACAGA 5’

Gag
SL2

LRI-I
Gag(Y-I)

LRI-II
Gag (Y-II)

U5 (X-I)
Gag (Y-I)

SL1

LRI-I
U5 (X-I)

LRI-II
U5 (X-II)

Region
B

B

RK1

PBS

pal SL

SL3

Wild Type (SJ2)

SL2

A

Y-II

RK2

X-I Y-I

X-II

-140.4

0.25

5’ acuccccgugucucuugccccc 3’
3’ UGAGGGGCACAGAGAACGGGG 5’

C

Figure 3.8: Mfold secondary structure predictions of the mutant transfer vector packaging signal RNAs containing stabilizing mutations
in the U5 sequences of the LRI-I and LRI-II.
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Figure 3.8. Mfold secondary structure predictions of the mutant transfer vector
packaging signal RNAs containing stabilizing mutations in the U5 sequences of
the LRI-I and LRI-II. (A) MPMV wild type transfer vector SJ2, ΔG= -124.7
kcal/mol. (B) RK1 containing substitution of four uridines involved in the wobble
base pairs with cytosines to stabilize LRI-I; ΔG= -134.9 kcal/mol. (C) RK2 mutant
transfer vector containing substitution of six uridines involved in the formation of
wobble base pairs in both LRI-I and LRI-II with cytosines; ΔG= -140.4 kcal/mol.
Note the significant loss in RPE in both RK1 and RK2 and the increase in the
stability of their structure when compared to the wild type due to the formation of GC base pairs. Purple and blue colors highlight the LRI-I and LRI-II regions,
respectively.
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predicted secondary structure. In RK1 and RK2, the substitution of the uridine
nucleotides involved in the wobble (G-U) base pairing with cytosines stabilized LRII and LRI-II, respectively. As expected, the predicted secondary structure of RK1
and RK2 did not reveal any disruptions in the structure when compared to the wild
type (Figure 3.8); however, the overall energy of RK1 and RK2 was observed to be
more negative (ΔG = -134.9 and -140.4, respectively) compared to the wild type (ΔG
= -124.7), suggesting that these two mutants became energetically more stable.
Considering that these mutations had no effect on the structure but resulted in only
further stabilization of the LRIs, while they had a significant effect on RNA
packaging suggests that the built-in flexibility of this region is important for its
function. In the wild type (SJ2) this flexibility is perhaps due to the presence of the
wobble G-U base pairs that was lost in RK1 and RK2 due to the introduced
mutations. Thus, the loss of the 4 G-U base pairs in RK1 did not only change the
primary structure of LRI-I, but also increased the rigidity of the secondary structure
since the free energy parameters used to predict the structure are sequence
dependent. This means that the fewer numbers of G-U base pairs in the structure,
the more rigid it is. Correlating these findings with the ~ 50% loss of packaging and
propagation of RK1 and RK2 mutant transfer vector RNAs indicates that the optimal
functionality of the LRIs is dependent upon the secondary structure with a moderate
flexibility.
The next set of mutants, RK3, RK4 and RK5 represent deletion mutants
where U5 (X-I), Gag (Y-I), and both were deleted respectively. The predicted
structures of mutants RK3 and RK5 showed that whenever the U5 sequence forming
the X-I strand were deleted, both LRI-I and LRI-II structures were lost in addition to
the Gag stem loop 1 (Figure 3.9). In RK4, the effect of the deletion of Gag sequence
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Figure 3.9: Mfold secondary structure predictions of the mutant transfer vector packaging signal RNAs containing systematic deletions in the
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Figure 3.9. Mfold secondary structure predictions of the mutant transfer vector
packaging signal RNAs containing systematic deletions in the LRI-I
complementary stem. (A) MPMV wild type transfer vector SJ2; ΔG= -124.7
kcal/mol. (B) RK3 where the U5 sequence (X-I) was deleted; ΔG= -112.8. (C) RK4
where the Gag (Y-I) sequence was deleted; ΔG= -116.5 kcal/mol. (D) RK5 which
contain a double deletion of both U5 and Gad strands of LRI-I; ΔG= -112.8
kcal/mol. Note the loss of LRI-I, Gag SL1 and LRI-II structures in RK3 and RK5
which is consistent with the drop in the free energy as both have ΔG= -112.8 where,
as in RK4, only LRI-I structure and Gag SL1 is disrupted, while LRI-II remains
intact. Purple and blue colors highlight the LRI-I and LRI-II regions, respectively.
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forming Y-I strand was observed on LRI-I only and Gag SL1 due to its proximity to
the deleted sequence, while LRI-II structure remained intact (Figure 3.9). All three
mutations had resulted in a complete loss of RNA packaging and propagation,
suggesting that the maintenance of LRI-I complementary stem structure is critical
for these functions. Additionally, we feel that the total free energy of the structure is
important as well for these functions. Thus, although the overall structure of this
region was maintained in these mutants, especially the pal SL, ssPurine-rich region,
SL3, and Region B (sequences/structures critical for RNA packaging and
dimerization), the free energy of the overall structure was lowered due to the effect
of the mutations compared to the wild type (ΔG = -112.8, -116.5, and -112.8
compared to -124.7 for the wild type). This perhaps result in fragile structures
(structures maintaining the shape but with lower energy), which are less stable than
the wild type structure since the lesser negative the free energy, the less stable is the
structure (Figure 3.9). This instability can explain the effect of the introduced
mutations on the RNA packaging as it probably affects the proposed interaction
between the NC domain of Gag protein with sequences augmenting RNA packaging.
The last two mutants, RK6 and 7, created to test the LRI-I were designed to
destabilize and re-create LRI-I structure, respectively, using non-viral heterologous
complementary sequences. As shown in figure 3.10, the structural prediction of
RK6 (where the U5 sequence forming X-I strand was substituted with heterologous
sequences, thus losing the complementarity between the two strands of the LRI-I)
maintained all the important structural motifs including LRI-II; however the
secondary structure of LRI-I was lost. The loss of LRI-I structure correlates well
with the loss of gRNA packaging and propagation. We believe that this loss also
destabilized the surrounding region, making the structure more flexible than needed
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Figure 3.10: Mfold secondary structure predictions of the mutant transfer vector packaging signal RNAs disrupting the complementarity of the
native LRI-I and recreating an artificial LRI.
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Figure 3.10. Mfold secondary structure predictions of the mutant transfer
vector packaging signal RNAs disrupting the complementarity of the native
LRI-I and recreating an artificial LRI. (A) MPMV wild type transfer vector SJ2;
ΔG= -124.7 kcal/mol. (B) RK6 where the U5 sequence (X-I) was substituted with
heterologous sequence thus disrupting the complementarity of LRI-I; ΔG= -115.4
kcal/mol. (C) RK7 where the LRI-1 complementarity was recreated by substituting
the Gag sequence (Y-I) with heterologous sequence complementary to the one
introduced in RK6; ΔG= -123.6 kcal/mol. Note the restoration of RPE in RK7 to
even more than the wild type level while it was abolished in RK6. This correlates
with the minimal free energy of RK7; ΔG = -123.6 kcal/mol that is close to the wild
type ΔG =-124.7. Purple and blue colors highlight the LRI-I and LRI-II regions,
respectively.
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(ΔG = -115.4), thus affecting its ability to function effectively.

The mutation

introduced in RK7, on the other hand, resulted in the restoration of the LRI-I
structure using non-viral heterologous sequences (Figure 3.10) and with it the RNA
packaging and propagation. The minimal free energy of the RK7 predicted structure
was calculated to be -123.6 which is very close to wild type value of -124.7 (Figure
3.10). Thus, compared to the mutation in RK1, which also created a heterologous
non-wild type LRI-I, RK1 was unable to restore RNA packaging and propagation.
RK1 has a free energy of -134.9 which we believe makes the structure too rigid for
effective function, thus supporting our hypothesis that the flexibility of this region is
as important as the structure of LRI-I. This difference in the calculated minimal free
energy of both mutants (RK1 and RK7) can be attributed to the number of G-C base
pairs in each LRI since none of the artificial LRIs contained G-U base pairing when
compared to the wild type (SJ2) LRI-I containing four G-U base pairing. In RK1,
eight out of the 13 base pairs were G-C base pairs which resulted in a very stable
stem; whereas in RK7, 2 out of 13 base pairs were G-C base pairs, thus lowering the
energy of the stem (Figure 3.10). Thus, it is rational to conclude that it is the
secondary structure of the LRI-I that is anchoring the overall secondary structure of
MPMV packaging signal RNA. In addition, it should have a final embedded energy
close to the wild type minimal free energy to maintain a certain level of flexibility
which seems to be the characteristic of LRI-I.

3.7.2. Structure-function relationship of the sequences involved in U5-Gag
LRI-II
Next, the structural analysis of the LRI-II mutants was conducted to
determine the structure-function relationship of LRI-II with RNA packaging. To
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summarize, the mutation in the LRI-II mutant RK8 replaced the predicted eight
nucleotides of LRI-II U5 (X-II) with heterologous sequences to disrupt the
complementarity with Y-II. Along the same lines the mutation in RK9 replaced U5
(X-II) sequence with a sequence identical to Gag (Y-II) sequence thus duplication
Gag (Y-II) sequence and disrupting LRI-II complementarity, while the mutation in
RK10 replaced Gag (Y-II) sequence with sequence from U5 (X-II) thus duplicating
Gag (Y-II) sequence and disrupting LRI-II complementarity as well. Finally, the
mutation in RK11 flipped the LRI-II stem-loop in a 180 degree manner to determine
its function relative to the context. As shown in figures 3.4 and 3.5, disruption of
LRI-II in any manner resulted in a complete abrogation of both RNA packaging and
propagation, suggesting that LRI-II is an important structure to maintain the optimal
RNA packaging and propagation of MPMV transfer vector RNAs. However, unlike
the LRI-I mutations, the mutational analysis of LRI-II revealed that it is its primary
sequence in the native context that is essential for MPMV RNA packaging and
propagation.
Such a conclusion pertaining to the role of LRI-II in MPMV RNA packaging
and propagation was further supported by the structural analysis of the LRI-II
mutants. Mutation of LRI-II by disruption of the X-II/Y-II stem complementarity in
RK8 and RK10 actually resulted in structures that led to the creation of stem
structures that resembled X-II in LRI-II; however, RNA packaging and propagation
of these mutants was still found to be abrogated (Figure 3.11). Similarly, disruption
of complementarity LRI-II in RK9 or inversion of LRI-II in RK11 (creating an
artificial LRI-II) both resulted in a complete abrogation of packaging and
propagation despite the reformation of an LRI-II-like stem in these mutants,
separated from LRI-I by a two nucleotide bulge (Figure 3.12). Likewise, a complete
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Figure 3.11: Mfold secondary structure predictions of the LRI-II mutant transfer vector packaging signal RNAs.

Y-II

126

127

Figure 3.11. Mfold secondary structure predictions of the LRI-II mutant
transfer vector packaging signal RNAs. (A) MPMV wild type transfer vector SJ2,
ΔG= -124.7 kcal/mol. (B) RK8 mutant transfer vector structure where the U5
sequence (X-II) was substituted with heterologous sequence, causing the loss of
complementarity between the LRI-II strands; ΔG= -122.9 kcal/mol. (C) RK10 where
the Gag (Y-II) sequence was substituted with X-II sequence of LRI-II which disrupts
the complementarity of LRI-II stem; ΔG= -120.6 kcal/mol. Note the abolished
packaging efficiency in both mutant transfer vectors which suggests the importance
of LRI-II complementary structure. Purple and blue colors highlight the LRI-I and
LRI-II regions, respectively.
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deletion of X-II in RK12, or its replacement with a heterologous sequence in RK13,
or reestablishment of LRI-II with heterologous sequences in RK14 (again creating
an artificial LRI-II) all resulted in complete abrogation of packaging and propagation
(Figure 3.5). Structural analysis of these mutants showed that LRI-II stem was
indeed disrupted in RK12 and RK13, especially RK13, thus explaining the loss of
function. In the case of RK14 even though an artificial LRI-II was re-created by
substituting the SHAPE-validated LRI-II sequences, in its native context, yet its
structural emergence was insufficient to restore function (Figure 3.13).

The

structure of RK14 showed that the LRI-II was recreated properly using the
heterologous sequences unlike RK11 where the predicted 8 nt LRI-II structure was
used to recreate the LRI. This observation further confirms the SHAPE-validated
structure of the LRI-II since artificial complementarity (based on predicted structure)
in RK11 failed to recreate LRI-II secondary structure (compare structures of RK11
and RK14 in figures 3.12 and 3.13 respectively). Together, these data confirm the
earlier conclusion that the primary sequence of LRI-II in its native context is critical
for its function.

3.7.3. Structure-function analysis of the mutations introduced in sequences
involved in forming stem loops at the 3’ end of the SHAPE-validated structure
In contrast to the LRI-I and LRI-II mutants, deletion analysis of the mutant
transfer vectors in the more distal 5’ UTR or Gag region revealed that single deletion
of any of the three targeted stem loops (SL3, Gag SL1 or Gag SL2) individually had
a marginal effect on RNA packaging and propagation (Figure 3.7). This can be
explained by the structural analysis of RK15, RK16 and RK17 where all the
structural motifs remained intact like the wild type except for the deletion of the
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Figure 3.12: Mfold secondary structure predictions of the LRI-II mutant transfer vector packaging signal RNAs.
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Figure 3.12. Mfold secondary structure predictions of the LRI-II mutant
transfer vector packaging signal RNAs. (A) MPMV wild type transfer vector SJ2,
ΔG= -124.7 kcal/mol. (B) RK9 mutant transfer vector structure where the U5
sequence (X-II) was substituted with the Gag (Y-II) sequence, causing a loss of
complementarity between the LRI-II strands; ΔG= -128.9 kcal/mol. (C) RK11
mutant transfer vector contains a flipped LRI-II secondary structure;, ΔG= -128.6
kcal/mol. Note that recreating the LRI-II in RK11 did not restore the packaging
efficiency (RPE= 0.025 relative to the wild type) which suggests the importance of
the primary sequence of the LRI-II in its native context. Purple and blue colors
highlight the LRI-I and LRI-II regions, respectively.

Gag
SL2

LRI-I
Gag(Y-I)

LRI-II
Gag (Y-II)

1.00

-124.7

RPE

∆G (kcal/mol)

Wild Type (SJ2)

SL1

LRI-I
U5 (X-I)

LRI-II
U5 (X-II)

Region
B

5’ CUUGUUCC 3’
3’ GAACGGGG 5’

PBS

U5 (X-II)
Gag (Y-II)

SL2

pal SL

A

SL3

Gag
SL1

Y-I

Y-II

-119.3

0.04

5’
∆
3’ 3’
3’ GAACGGGG 5’

RK12

X-I

B

-125.8

0.03

5’ aggaggagg 3’
3’ GAACGGGG 5’

RK13

X-I

Y-I

C

Figure 3.13: Mfold secondary structure predictions of the LRI-II mutant transfer vector packaging signal RNAs.

Y-I

-131.8

0.12

5’ aggaggagg 3’
3’ uccuccucc 5’

RK14

X-I

X-II Y-II

D

131

132

Figure 3.13. Mfold secondary structure predictions of the LRI-II mutant
transfer vector packaging signal RNAs. (A) MPMV wild type transfer vector SJ2;
ΔG= -124.7 kcal/mol. (B) RK12 where the U5 sequence (X-II) of the SHAPEvalidated LRI-II was deleted; ΔG= -119.3 kcal/mol. (C) RK13 where the U5
sequence (X-II) of the SHAPE-validated LRI-II was substituted with heterologous
sequence to disrupt the complementarity between X-II and Y-II of the LRI-II
structure; ΔG= -125.8 kcal/mol. (D) RK14 mutant transfer vector where an artificial
LRI-II is created by substituting the Y-II strand with heterologous sequence
complementary to the one introduced in RK13, thus restoring the complementarity of
between X-II and Y-II; ΔG= -131.8 kcal/mol. Note that despite the presence of a
complementary LRI in RK14, the RPE was still only 0.116. This means that the
primary structure of LRI-II is essential unlike LRI-I.
highlight the LRI-I and LRI-II regions, respectively.

Purple and blue colors
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targeted stem loop (Figure 3.14). Interestingly, in RK15, the ssPurine-rich region
became partially base-paired due to the deletion of SL3. Moreover, six nucleotides
in region B which are base-paired in the wild type structure lost their base pairing.
Region B has previously been shown to be important for MPMV RNA packaging
(Schmidt et al., 2003; Jaballah et al., 2010). This may explain the slight reduction in
packaging and propagation observed in this mutant (Figure 3.7).
The double deletions which involved ∆SL3 with either ∆Gag SL1 or ∆Gag
SL2 in separate mutants (RK18 and RK19, respectively) showed a more pronounced
effect on RNA packaging and propagation when compared to the wild type (Figure
3.7). Structural predictions of these two mutants revealed the same changes seen in
RK15 where the ssPurine-rich region became partially base-paired and in region B
the six nucleotides which are part of the ssPurines repeat sequence became single
stranded (Figure 3.15). In the case of triple deletion, RK20, which involved ∆SL3,
∆Gag SL1 and ∆ Gag SL2, the RNA packaging and propagation were further
reduced (Figure 3.7). Consistent with secondary structure predictions of RK15,
RK18 and RK19, the ssPurine-rich region became partially base paired in RK20 as
well, while maintaining the LRIs (Figuers 3.14 and 3.15). This change in structure
was due to the deletion of SL3 which is common to all four mutants. Thus, our
overall conclusion is that as long as the two LRIs are maintained, deletion of these
three stem loops does not have a detrimental effect on the packaging/propagation
potential of the MPMV transfer vector RNAs.
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Figure 3.14: Mfold secondary structure predictions of the mutant transfer vector packaging signal RNAs containing individual deletions
of SL3, Gag SL1, and Gag SL2
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Figure 3.14. Mfold secondary structure predictions of the mutant transfer
vector packaging signal RNAs containing individual deletions of SL3, Gag SL1,
and Gag SL2. (A) MPMV wild type transfer vector SJ2; ΔG = -124.7 kcal/mol. (B)
RK15 containing a deletion of SL3; ΔG = -107.9 kcal/mol. (C) RK16 mutant transfer
vector containing a deletion of Gag SL2; ΔG = -119.5 kcal/mol. (D) RK17 mutant
transfer vector containing a deletion of Gag SL1; ΔG=1116.6 kcal/mol. Purple and
blue colors highlight the LRI-I and LRI-II regions, respectively.
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Figure 3.15: Mfold secondary structure predictions of the mutant transfer vector packaging signal RNAs containing multiple deletions
of SL3, Gag SL1, and Gag SL2.
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Figure 3.15. Mfold secondary structure predictions of the mutant transfer
vector packaging signal RNAs containing multiple deletions of SL3, Gag SL1,
and Gag SL2. (A) MPMV wild type transfer vector SJ2; ΔG = -124.7 kcal/mol. (B)
RK18 containing a double deletion of SL3 and Gag SL1; ΔG = -99.8 kcal/mol. (C)
RK19 mutant transfer vector containing a double deletion of SL3 and Gag SL2; ΔG
= -102.7 kcal/mol. (D) RK20 mutant transfer vector containing a triple deletion of
SL3, Gag SL1, and Gag SL2; ΔG=194.6 kcal/mol. Purple and blue colors highlight
the LRI-I and LRI-II regions, respectively.
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Chapter 4: Discussion
A number of findings over the last decade have significantly advanced our
understanding of the mechanism of retrovirus RNA packaging process. The fact that
packaging signals of different retroviruses share the common characteristic of
folding into secondary structural motifs emphasizes the importance of such structural
elements to RNA packaging.

The 5’ end of MPMV genome (from the first

nucleotide in R up to 120 bp of Gag) contains a number of sequence and structural
elements that have been shown to be important for RNA packaging and dimerization
(Schmidt et al., 2003; Jaballah et al., 2010; Aktar et al., 2013; Figure 1.13). One of
the distinguishing features of the MPMV packaging signal RNA secondary structure
is the long-range interactions of 5’ (U5) and 3’ (Gag) complementary sequences,
forming two LRIs (LRI-I and LRI-II) that are believed to anchor its overall
secondary structure (Jaballah et al., 2010; Aktar et al., 2013; Figure 1.13). Both of
these LRIs have been found to be phylogenetically conserved among different
MPMV strains at the structure level, as well as in maintaining a very high degree of
complementarity between U5 and Gag sequences (Aktar et al., 2013; Figure 1.14
and 1.15). LRIs have been found to be conserved in several retroviruses including
HIV-1, FIV, and MMTV (Paillart et al., 2002; Abbink and Berkhout, 2003; Kenyon
et al., 2008; Kenyon et al., 2011, Aktar et al., 2014). Despite the fact that there are
substantial sequence heterogeneities among human, simian, and feline lentiviruses,
the preservation of such LRIs in all HIV-1, HIV-2, simian immunodeficiency virus
(SIV), and FIV isolates offers additional proof for the functional significance of
LRIs in retroviral life cycle (Paillart et al., 2002; Kenyon et al., 2008; Kenyon et al.,
2011). Such a pivotal role of LRIs is further evidenced by the fact that mutations
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that destabilize the complementarity of these interactions affect several important
steps in retroviral life-cycle, including RNA packaging and dimerization (Paillart et
al., 2002; Abbink and Berkhout, 2003; Rizvi et al., 2010).
Unlike other retroviruses with one identified LRI, MPMV contains two LRIs
(LRI-I and LRI-II; Figure 1.13) both of which maintain the interaction between U5
and Gag sequences (Paillart et al., 2002; Abbink and Berkhout, 2003; Kenyon et al.,
2008; Kenyon et al., 2011, Aktar et al., 2014). The work presented here employed
mutational and structural analyses of these LRIs (which appears to be anchoring the
major structural motifs) as well as three other stem loops (SL3, Gag SL1, and Gag
SL2) that are thought to provide architectural support to the overall RNA secondary
structure to study their significance during MPMV RNA packaging. The results
presented here provide data validating the existence and the biological significance
of the two LRIs. These further reveal that the two LRIs function in different
manners mechanistically with LRI-I being important at the secondary structural
level, while LRI-II being important at both the primary sequence as well as structural
levels (Figures 3.3 and 3.5). Finally, deletion and structural analysis of the three
additional stem loops targeted reveal that SL3, Gag SL1, and Gag SL2 have
secondary significance compared to the LRIs during RNA packaging and
propagation and serve mainly to hold the entire secondary structure of this region
together with redundant functions such that if one stem loop is deleted, the others
can compensate for its absence (Figure 3.7). In summary, our results reveal that the
5’ end of the MPMV genomic RNA is held together by two LRIs and the additional
stem loops (SL3, Gag SL1, and Gag SL2) help maintain the proper folding and
stability of the secondary structure for function even though none of these stem
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loops by themselves are directly involved in MPMV RNA packaging process
(Figure 3.7).
Functionally, the U5-Gag LRI-I of MPMV resembles the R/U5-Gag
heptanucleotide FIV LRI, where its presence as a structural motif rather than its
primary sequences is essential for RNA packaging (Rizvi et al., 2010). However,
the MPMV LRI-I differs from the FIV heptanucleotide LRI in the observation that
re-establishment of the LRI-I structure using any complementary sequences does not
necessarily restore RNA packaging and propagation.

Note the lack of RNA

packaging in LRI-I re-establishing mutant RK1, while packaging was restored by
RK7 (Figure 3.3). RK1 is a LRI-1-stabilizing mutant where the G-U base pairs had
been substituted with G-C base pairs to make the LRI-I more stable, without
disrupting the RNA structure (Figures 3.3 and 4.1). On the other hand, heterologous
complementary sequences were used to substitute the original LRI-I in RK7 (Figures
3.3 and 4.1).

Even though in both cases the structure of the region remained

identical and the primary sequence had been changed, only RK7 was able to restore
RNA packaging and propagation, but not RK1 (Figures 3.3 and 4.1). We believe
that this is due to the difference in the free energy (ΔG) of the structures that were
created (Figure 4.1). Thus, the re-established heterologous LRIs should have a
minimal embedded free energy at a level that is close to that of the wild type (SJ2)
level. The free energy values of the predicted secondary structures of the mutant
transfer vectors RK1 and RK7 and their relative packaging efficiencies clearly favor
this argument (Figure 4.1).
This energy-sensitive phenomenon can be attributed to the fact that the LRI-I
structure should have a certain level of flexibility to fulfill its function. This
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Figure 4.1: Mfold secondary structure predictions of the mutant transfer vector packaging signal RNAs containing mutations in LRI-I.
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Figure 4.1. Mfold secondary structure predictions of the mutant transfer vector
packaging signal RNAs containing mutations in LRI-I. (A) MPMV wild type
transfer vector SJ2; ΔG = -124.7 kcal/mol. (B) RK1 containing substitution of four
uridines involved in the wobble base pairs with cytosines to stabilize LRI-I; ΔG= 134.9 kcal/mol.

(C) RK7 where the LRI-1 complementarity was recreated by

substituting the Gag sequence (Y-I) with heterologous sequence complementary to
the one introduced in RK6; ΔG= -123.6 kcal/mol. Purple and blue colors highlight
the LRI-I and LRI-II regions, respectively.
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flexibility comes from the low affinity base pairing (A-U or G-U; Mathews et al.,
1999) being part of the complementary base pairing within the wild type LRI-I
structure. The minimal free energy calculated by the Mfold algorithm indicates the
flexibility of the RNA structure based on the cumulative energies of the base pairing
between the nucleotides involved in the RNA sequence. The secondary structure
with the minimum free energy is the most stable structure (Mathews et al., 1999). A
careful analysis of the complementary sequences forming wild type (SJ2) and
artificial LRI-I mutants RK1 and RK7 revealed an interesting base pairing
composition which favors the flexibility argument put forwarded above.

For

example, in the case of the wild type (SJ2), 9/13 (~70%) were A-U or G-U (5 A-U, 4
G-U, and 4 G-C base pairs), with a free energy (ΔG) of -124.7, while in the case of
the LRI-I re-establishing mutant RK1 which could not restore RNA packaging, only
5/13 (38%) were A-U (5 A-U and 8 G-C base pairs) with a free energy (ΔG) of 134.9. Finally, in the case of LRI-I re-establishing mutant RK7 which restored RNA
packaging, 11/13 (~85%) were A-U complementary base pairs (11 A-U and 2 G-C
base pairs) with a free energy (ΔG) of -123.6 (Figure 4.1). Our interpretation of this
data is that the increased embedded energy due to the stable G-C base pairing in
RK1 made the LRI-I structures more rigid than needed, resulting in the significant
drop in MPMV RNA packaging and propagation observed (Figure 4.1). It is well
known that the genomic RNAs are active players in many critical stages in the
retroviral life cycle, including processes that are driven mainly by the proper 3dimensional folding of multiple RNA domains to recruit necessary viral and host
factors required for activity.

This flexibility, at a moderate level, is of great

importance to the RNA as it is a dynamic structure that undergoes several
intramolecular and intermolecular interactions (for example, RNA-RNA and Gag-
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NC-RNA interactions) during the RNA dimerization and packaging processes.
Therefore, even though the LRI-I structure is important, it must maintain a certain
level of flexibility (signified by its free energy) to allow further folding or unfolding
of the region, as the need may arise during the virus life cycle.
The case of LRI-II, however, was observed to be different as the results
obtained suggest that it is its primary sequence in its native structural context that is
essential for RNA packaging and propagation. LRI-II stem destabilizing mutations
in the LRI-II in mutants RK8-RK10, RK12 and RK13 resulted in a complete loss of
RNA packaging and propagation (Figure 3.5).

Re-establishment of the LRI-II

structure in RK14 using heterologous complementary sequences of equal length also
failed to restore packaging or propagation of MPMV transfer vector RNAs (Figure
4.2). Even RK11, the mutant with the primary sequence of LRI-II intact, but in the
opposite orientation was unable to restore LRI-II function despite the presence of the
primary sequence (Figure 3.5). This can be attributed due to a loss of secondary
structure of this mutant, similar to RK9 that contained the heterologous stem
disrupting mutation in LRI-II strand (Figures 3.12 and 4.2). Together, these results
point to the conclusion that the primary sequence of LRI-II in its native structural
context is critical for its function. However, the possibility remains that the energy
requirement of the re-established LRI-II may not have been met since the ΔG of
RK14 was observed to be -131.8, much lower that of the wild type, making the RNA
more rigid than functionally desired (Figure 4.2). It would be interesting to test an
LRI-II-restoring mutant that restores the free energy of this region to the wild type
levels to confirm or refute this possibility.
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Figure 4.2. Mfold secondary structure predictions of the mutant transfer vector
packaging signal RNAs containing mutations in LRI-II. (A) MPMV wild type
transfer vector SJ2; ΔG = -124.7 kcal/mol. (B) RK11 mutant transfer vector contains
a flipped LRI-II secondary structure; ΔG= -128.6 kcal/mol.

(C) RK14 mutant

transfer vector where an artificial LRI-II is created by substituting the Y-II strand
with heterologous sequence complementary to the one introduced in RK13, thus
restoring the complementarity of between X-II and Y-II; ΔG= -131.8 kcal/mol.
Purple and blue colors highlight the LRI-I and LRI-II regions, respectively.
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Our mutational analysis further confirms the SHAPE-validated structure of
LRI-II (Aktar et al., 2013) compared to the predicted one by Mfold (Jaballah et al.,
2010). When attempts were made to disrupt LRI-II using the Mfold predicted LRIII, we observed that the mutation that was supposed to recreate the LRI-II in RK11,
was unable to restore the structure (Figure 4.2). However, this was not the case with
RK14, the clone with the compensatory heterologous mutation that re-created LRI-II
based
on the SHAPE-validated structure. This structure maintains an unpaired uridine at
position 62 (U62), making the length of LRI-II 9 nucleotides, rather than 8
nucleotide as predicted earlier (Jaballah et al., 2010).
As has been shown, the MPMV SHAPE-validated structure appears to be
anchored by complementary U5 and Gag sequences forming the LRIs. These LRIs
have been suggested to play architectural role in stabilizing the RNA secondary
structure of the 5’ UTR sequences that are important for MPMV RNA packaging.
Based on the spatial organization of the SHAPE-validated structure, it is reasonable
to suggest that while LRIs stabilize 5’ UTR sequences, the overall RNA secondary
structure is further architecturally held together by the three stem loops (SL3, Gag
SL1, and Gag SL2) comprising of sequences from the distal parts of the 5’ UTR and
Gag (but excluding the Gag sequences involved in forming U5-Gag LRIs; Figure
3.7). Deletion of these stem loops either individually or in multiples revealed that
they were dispensable for RNA packaging and propagation (Figure 3.7). It required
a rather large 102 nucleotide triple stem loop deletion to finally reduce packaging
and propagation by five to ten-folds (RK20 in Figure 3.7). These observations
support our hypothesis that the MPMV packaging signal RNA secondary structure
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can be divided into two parts horizontally.

The upper part of the structure

comprising of several structural motifs (for example regions A and B, the
dimerization initiation site in pal SL, and ssPurine-rich region) that have been shown
to be important for MPMV RNA packaging and dimerization (Schmidt et al., 2003;
Jaballah et al., 2010; Aktar et al., 2013), and the lower part of the structure
containing the non-LRI forming three stem loops, that serve to provide architectural
support to the overall RNA secondary structure during the process of RNA
packaging and dimerization (Figure 3.7).
Consistent with this hypothesis, our results confirm that the primary
sequence forming SL3 found in close vicinity of the ssPurine-rich region is not
important since its deletion in RK15 only marginally affected RNA packaging or
propagation (Figure 3.14).

Substitution of the deleted 33 nt of SL3 with a

heterologous sequence maintained the overall structure, including the ssPurine-rich
region in its single stranded form (hypothetical Structure A in Figure 4.3). In
hypothetical structure A, 33 nt forming SL3 were substituted with the 39 nt sequence
of Gag SL1. The structure prediction of the hypothetical clone A revealed an intact
structure with Gag SL1 secondary structure being duplicated at the SL3 location
while still maintaining the same apical loop of the native Gag SL1 (Figure 4.3).
Similarly, in hypothetical Structure B, two of the three stem loops namely SL3 and
Gag SL1 sequences were substituted with the 30 nt sequence of Gag SL2.
Consistent with hypothetical Structure A, the predicted secondary structure of
hypothetical clone B showed a copy of Gag SL2 structure at the site of the deleted
SL3 and Gag SL1 while still maintaining the same apical uridine loop of the native
Gag SL2 as well as the overall secondary structure of the MPMV packaging signal
RNA intact (Figure 4.3). Together, structural analyses of the single and multiple
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Figure 4.3. Mfold secondary structure predictions of the hypothetical mutant
transfer vector packaging signal RNAs containing stem loop substitution
mutations in the packaging signal. (A) MPMV wild type transfer vector SJ2; ΔG =
-124.7 kcal/mol. (B) Mutant A containing a substitution of SL3 with Gag SL1; ΔG=
-120.6 kcal/mol. (C) Mutant B containing a double substitution mutation of SL3 and
Gag SL1 with Gag SL2; ΔG= -117.0 kcal/mol. Purple and blue colors highlight the
LRI-I and LRI-II regions, respectively.
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deletion mutants (RK15-RK20) and hypothetical clones (A and B) confirm the
spatial role of the SL3 sequences in MPMV genomic RNA packaging which is
consistent, as has been proposed previously (Jaballah et al., 2010).
Mutational analysis of MPMV LRIs involving complementary U5 and Gag
sequences is in conformity with earlier observations which have shown the role Gag
sequences in RNA packaging, further arguing in favor of the existence of LRIs in
vivo and their functional role in MPMV life cycle. For example, Schmidt et al., have
shown that deletion of the Gag sequences involved in U5-Gag LRIs, while
maintaining the U5 sequences that are involved in U5-Gag LRI-I, severely
diminished MPMV RNA packaging ability (Schmidt et al., 2003). Moreover, when
the Gag sequences were cloned back into the transfer vector, resulting in the
maintenance of the now known U5-Gag LRIs, RNA packaging was restored to the
wild type levels (Schmidt et al., 2003). These observations are consistent to those
that have been shown in other retroviruses (HIV-1, HIV-2, and FIV) where
complementary sequences in the R/U5 region and within Gag interact to stabilize the
overall RNA secondary structure essential for RNA dimerization and packaging
(Paillart et al. 2002; Abbink and Berkhout 2003; Kenyon et al. 2008, 2011; Song et
al. 2008; Rizvi et al. 2010; Lu et al. 2011b).
LRI structures have also been shown to be important for RNA dimerization
in HIV-1 as the presence of a duplex called U5-AUG forms between nucleotides
105-115 in the U5 region and 334-344 surrounding the AUG initiation codon
(Abbink and Berkhout, 2003). This duplex is present in the branched multiple
hairpin (BMH) conformation of the HIV-1 gRNA which allows for dimerization as
well as packaging. The U5-AUG duplex contains four G-U base pairs out of its 11
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base pairs and it has been shown that stabilizing the U5-AUG duplex G-U base pairs
by converting them to G-C and A-U base pairs increase the dimer formation rate
when compared to the wild type. Such an increase has been attributed to the fact
that any mutation introduced into the U5 portion of the duplex destabilizes the long
distant interactions (LDI) conformation of HIV-1 RNA and induces a shift from the
LDI to the BMH conformation (Abbink and Berkhout, 2003). Moreover, stabilizing
the duplex by changing the base pairing pattern seems to hold tightly the structure of
BMH conformation, resulting in increase of dimerization more than the wild type
(Abbink and Berkhout, 2003). This is in sharp contrast to the observation made in
the case of MPMV LRIs since stabilizing the interaction between the U5 and Gag
sequences in LRI-I as well as LRI-II severely affected RNA packaging and
propagation (Figures 3.3 and 3.8). The interpretation of the negative effect on
MPMV RNA packaging and propagation when the LRIs are further stabilized, as
discussed above, could be attributed to the differences in the minimal free energy
between the stabilized, therefore more rigid LRIs, and the wild type flexible LRI
structures (Figure 4.1). Thus, the flexible nature of LRIs is necessary for its efficient
function since it ensures that the genomic RNA can properly fold or unfold
dynamically during dimerization and packaging.
Besides stabilizing the secondary structure of the packaging signal RNA, the
structural role of LRIs in packaging may reside in the specific selection of RNA that
is to be packaged into the virus particle. The selection strategy depends on the fact
that the LRI-I and LRI-II structures involve sequences within Gag downstream of
the mSD which should restrict such a conformation only to the full length unspliced
RNA. A similar sort of selection mechanism has also been suggested for HIV-1
gRNA containing U5-AUG duplex because in such a conformation, the Gag AUG
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start codon is occluded, downregulating Gag protein translation and thereby
allowing the specific packaging of the full length unspliced RNA in the budding
virus particles (Abbink and Berkhout, 2003). Similar to this scenario, the MPMV
LRIs may also have a role in the translation of the Gag protein since the guanine (G)
residue of the Gag AUG start codon is within the U5-Gag complementary sequence
of LRI-II. This plausibly could allow the regulation of temporal switch between
viral protein synthesis and packaging, conferring high specificity of packaging that is
limited exclusively to the full length unspliced RNA.
The work presented here, to the best of our knowledge, is the first study that
validate the existence and biological significance of the two LRIs at the 5’ end of
the MPMV genome that have been shown to be important for its RNA packaging
and dimerization (Jaballah et al., 2010; Aktar et al., 2013). While these LRIs play an
important role in augmenting MPMV RNA packaging, they function at different
levels to facilitate this crucial step in the viral life cycle.

Specifically, LRI-I

functions at the secondary structural level, whereas LRI-II functions at both the
primary sequence as well as in its native structural context levels. Our results also
suggest that U5-Gag LRIs have a more important architectural role in stabilizing the
structure of the 5’ UTR sequences, while the three stem loops (SL3, Gag SL1, and
Gag SL2) may have a more secondary role in stabilizing the overall RNA secondary
structure of this region. The data presented here should enhance our understanding
pertaining to the molecular intricacies involved during the MPMV RNA packaging
and dimerization processes.
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Chapter 5: Conclusions & Recommendations
5.1.

Conclusions
Selective and specific genomic RNA (gRNA) packaging into the budding

virion is an essential step in retroviral life cycle. The specificity of gRNA packaging
is conferred by recognition of specific cis-acting sequences, the packaging signal
(Ψ), present at the 5’end of the retroviral genome, which interacts with the
nucleocapsid

protein.

Employing a

combination

of

structural

prediction,

phylogenetic, biochemical, and genetic analyses, we have earlier shown that MPMV
packaging determinants (5’ UTR and beginning of Gag) fold into a stable structure
comprising of several stable stem loops (Figure 1.13; Schmidt et al., 2003, Jaballah
et al., 2010; Aktar et al., 2013).

The prevailing structural model reveals a

characteristic feature of long-range interactions (LRIs) involving the complementary
sequences within the U5- and Gag regions. These LRIs (LRI-I and LRI-II) have
been found to be phylogenetically conserved, maintaining a high degree of
complementarity between different strains of MPMV both at the secondary structure
as well as the primary sequence levels (Figures 1.14 and 1.15; Aktar et al., 2013).
Based on these observations, we hypothesized that LRI-II and LRI-II may play
architectural role in stabilizing the RNA secondary structure of MPMV packaging
signal RNA which is further held together by three stem loops (SL3, Gag SL1, and
Gag SL2), comprising of sequences from the distal parts of the 5’ UTR and Gag (but
excluding the Gag sequences involved in forming U5-Gag LRIs; Figure 3.6).
The higher order features of the MPMV packaging signal RNA have not
been investigated empirically for their significance to MPMV replication.
Therefore, to establish the biological significance of the LRIs and the other three
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stem loops (SL3, Gag SL1, and Gag SL2) within the MPMV packaging signal RNA,
we introduced a series of mutations in this region. As a first step, we tested whether
thes two LRIs could potentially play a role in MPMV gRNA packaging by
maintaining the overall RNA structure or whether this involvement was at the
primary sequence level, or both. Towards this end, a series of deletion/substitution
mutations were introduced into the U5 and Gag sequences that either disrupted the
complementarity or restored it artificially using non-viral sequences (Figures 3.2 and
3.4). Next, a systematic deletion analysis of the sequences involved in forming SL3,
Gag SL1, and Gag SL2 was performed (Figure 3.6). These mutants were tested in a
biologically relevant in vivo packaging and transduction assay for their effect on
RNA packaging and propagation (Figures 3.3, 3.5, and 3.7). Finally, an attempt was
made to establish structure-function relationships between the biological effects of
the introduced mutations and their predicted RNA secondary structure. Results
obtained from these multi-pronged approaches have revealed that:
1. It is the secondary structure of the LRI-I, with a moderate level of flexibility in
the complementary sequences between U5 and Gag sequences, that is essential
for MPMV RNA packaging and propagation. This argument stems from the
observation that increasing the embedded energy due to the substitution of stable
G-C base pairing in mutant clone RK1 made the LRI-I structures more rigid than
what was needed, causing a significant drop in MPMV RNA packaging (Figure
4.1).

Consistent with this observation, re-establishment of LRI-I with

heterologous sequences in RK7 restored both the minimal free energy embedded
in the secondary structure as well as RNA packaging to the wild type levels
(Figure 4.1).
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2. LRI-II functions at both the primary sequence as well as in its native structural
context levels. This is substantiated by the observations that recreation of the
artificial LRI-II using primary viral sequences in mutant clone RK11 (retaining
the primary viral sequences involved in forming LRI-II, however, in an opposite
orientation, thus re-establishing an artificial LRI-II) failed to restore packaging
or propagation to wild-type levels (Figure 4.2).
3. Sequences involved in forming SL3, Gag SL1, and Gag SL2 do not play
crucial role at individual levels during MPMV RNA packaging and
propagation since deleting these stem loops individually only marginally
affected RNA packaging when compared to the wild type (Figure 3.7).
Furthermore it is only when a more drastic 102 nt deletion of sequences
involved in forming SL3, Gag SL1, and Gag SL2 was introduced in mutant
clone RK20 that a significant drop in RNA packaging and propagation could be
observed (Figure 3.7).
4. U5-Gag LRIs have a more important architectural role in stabilizing the structure
of the 5’ UTR, while the three stem loops (SL3, Gag SL1, and Gag SL2) seems
to have a rather secondary role in stabilizing the overall higher order features of
MPMV packaging signal RNA.

5.2.

Recommendations

Work presented in this thesis has systematically addressed and unraveled the role of
LRIs in MPMV RNA packaging process. As always, this study has also raised new
questions which need to be addressed further in order to unravel the molecular
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intricacies involved in MPMV RNA packaging. A potential future project to build
upon this work could address the following:
1. Validate the mutant transfer vector RNA structure predictions employing
biochemical approaches such as SHAPE to correlate the biological results that
are obtained with the validated structure rather than the predicted ones.
2. Considering the importance of the embedded energy in RNA secondary
structures, create an artificial LRI-II- restoring mutant that maintains the free
energy of this region to the wild type levels and monitor the effects of this
mutant in on RNA packaging to ascertain whether a certain energy requirement
of the re-established LRI-II is required or not to restore function.
3. Mfold predictions have suggested that the primary sequence involved in the
formation of SL3 is not essential for the RNA packaging and propagation.
Therefore, to further confirm this observation, a mutant clone could be designed
in which SL3 is substituted with a heterologous sequence and tested for function.
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